

1 **The polarity and specificity of SARS-CoV2 -specific T lymphocyte** 2 **responses determine disease susceptibility**

3 Jean-Eudes FAHRNER^{1,2,3,4}, Agathe CARRIER^{*2,3}, Lyon COVID study group^{*5-8}, Eric DE
4 SOUSA^{*13}, Damien DRUBAY^{*2,12}, Agathe DUBUISSON^{*2,3}, Arthur GERAUD^{*2,9,10}, Anne-
5 Gaëlle GOUBET^{*1,2,3}, Gladys FERRERE^{*2,3}, Yacine HADDAD^{*2,3}, Imran LAHMAR^{*1,2,3},
6 Marine MAZZENGA^{*2,3}, Cléa MELENOTTE^{*2,3,11}, Marion PICARD^{*2,3}, Cassandra
7 THELEMAQUE^{*2,3}, Luigi CERBONE^{2,9}, Joana R. LÉRIAS¹³, Ariane LAPARRA^{2,9,10}, Alice
8 BERNARD^{2,9,10}, Benoît KLOECKNER^{2,3}, Marianne GAZZANO^{2,3}, François-Xavier
9 DANLOS^{1,2,3}, Safae TERRISSE^{2,3}, Carolina ALVES COSTA SILVA^{1,2,3}, Eugénie PIZZATO^{2,3},
10 Caroline FLAMENT^{2,3}, Pierre LY^{2,3}, Eric TARTOUR^{14,15}, Lydia MEZIANI², Abdelhakim
11 AHMED-BELKACEM¹⁶, Makoto MIYARA¹⁷, Guy GOROCHOV¹⁷, Fabrice BARLESI^{2,9,18},
12 Caroline PRADON^{2,19,20}, Emmanuelle GALLOIS^{2,21}, Fanny POMMERET^{2,22}, Emeline
13 COLOMBA^{2,9}, Pernelle LAVAUD^{2,9}, Eric DEUTSCH^{1,2,23,24}, Bertrand GACHOT^{2,25}, Jean-
14 Philippe SPANO²⁶, Mansouria MERAD^{2,27}, Florian SCOTTE^{2,22}, Aurélien
15 MARABELLE^{1,2,3,9,10,28}, Frank GRISCELLI^{2,21,29,30,31}, Jean-Yves BLAY^{32,33,34}, Jean-Charles
16 SORIA^{1,2}, Fabrice ANDRE^{1,2,9,35}, Mathieu CHEVALIER³⁶, Sophie CAILLAT-ZUCMAN³⁷,
17 Florence FENOLLAR³⁸, Bernard LA SCOLA³⁸, Guido KROEMER^{39,40,41,42,43,44}, Markus
18 MAEURER^{**13,45,46,47}, Lisa DEROSA^{**1,2,3,9}, and Laurence ZITVOGEL^{**1,2,3,28}.

19

20 *Co-second authors, listed in alphabetical order, have equally contributed to this work.

21 **Co-last authors have equally contributed to this work.

22

23 ¹Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.

24 ²Gustave Roussy, Villejuif, France

25 ³Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy,
26 Villejuif, France.

27 ⁴Transgene S.A., Illkirch-Graffenstaden, France

28 ⁵Open Innovation & Partnerships (OIP), bioMérieux S.A., Marcy l'Etoile, France. R&D –
29 Immunoassay, bioMérieux S.A., Marcy l'Etoile, France.

30 ⁶Joint Research Unit Hospices Civils de Lyon-bioMérieux, Civils Hospices of Lyon, Lyon
31 Sud Hospital, Pierre-Bénite, France.

32 ⁷International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS
33 UMR 5308, ENS, UCBL, Lyon, France.

34 ⁸Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.

35 ⁹Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France.

36 ¹⁰Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy,
37 Villejuif, France

38 ¹¹Aix-Marseille Université, Institut de Recherche pour le Développement, Assistance

39 Publique – Hôpitaux de Marseille, Microbes Evolution Phylogeny and Infections, Marseille,
40 France.

41 ¹²Département de Biostatistique et d'Epidémiologie, Gustave Roussy, Université Paris-Saclay,
42 Villejuif, France.

43 ¹³ImmunoTherapy/ImmunoSurgery, Champalimad Centre for the Unknown, Lisboa,
44 Portugal.

45 ¹⁴Department of Immunology, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.

46 ¹⁵PARCC, INSERM U970

47 ¹⁶Univ Paris Est Creteil, INSERM U955, IMRB, Creteil, France.

- 48 ¹⁷Sorbonne Université/Institut National de la Santé et de la Recherche Médicale, U1135,
49 Centre d'Immunologie et des Maladies Infectieuses, Hôpital Pitié-Salpêtrière, Assistance
50 Publique – Hôpitaux de Paris, Paris, France.
- 51 ¹⁸Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France.
- 52 ¹⁹Centre de ressources biologiques, ET-EXTRA, Gustave Roussy, Villejuif, France.
- 53 ²⁰Département de Biologie Médicale et Pathologie Médicales, service de biochimie, Gustave
54 Roussy, Villejuif, France.
- 55 ²¹Département de Biologie Médicale et Pathologie Médicales, service de microbiologie,
56 Gustave Roussy, Villejuif, France.
- 57 ²²Département Interdisciplinaire d'Organisation des Parcours Patients, Gustave Roussy,
58 Villejuif, France.
- 59 ²³Institut National de la Santé et de la Recherche Médicale, U1030, Gustave Roussy, Villejuif,
60 France.
- 61 ²⁴Département de Radiothérapie, Gustave Roussy, Villejuif, France.
- 62 ²⁵Service de Pathologie Infectieuse, Gustave Roussy, Villejuif, France.
- 63 ²⁶Department of Medical Oncology, Pitié-Salpêtrière Hospital, APHP, Sorbonne Université,
64 Paris, France
- 65 ²⁷Service de médecine aigue d'urgence en cancérologie, Gustave Roussy, Villejuif, France.
- 66 ²⁸Center of clinical investigations BIOTHERIS, INSERM CIC1428, Gustave Roussy,
67 Villejuif, France
- 68 ²⁹Institut National de la Santé et de la Recherche Médicale – UMR935/UA9, Université Paris-
69 Saclay, Villejuif, France.
- 70 ³⁰INGESTEM National IPSC Infrastructure, Université de Paris-Saclay, Villejuif, France.
- 71 ³¹Université de Paris, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, France.
- 72 ³²Centre Léon Bérard, Lyon, France.
- 73 ³³Université Claude Bernard, Lyon, France.
- 74 ³⁴Unicancer, Paris, France.
- 75 ³⁵Institut National de la Santé et de la Recherche Médicale, U981, Gustave Roussy, Villejuif,
76 France.
- 77 ³⁶INSERM UMR 976, Institut de Recherche Saint-Louis, Université de Paris, Paris, France.
- 78 ³⁷Laboratory of Immunology, AP-HP, Hôpital Saint Louis, INSERM UMR1149, Université
79 de Paris, Paris, France.
- 80 ³⁸Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France.
- 81 ³⁹Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer,
82 Université de Paris, Sorbonne Université, Inserm U1138, Institut Universitaire de France,
83 Paris, France.
- 84 ⁴⁰Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Université Paris
85 Saclay, Villejuif, France.
- 86 ⁴¹Pôle de Biologie, Hôpital Européen George Pompidou, Assistance Publique – Hôpitaux de
87 Paris, Paris, France.
- 88 ⁴²Université de Paris, Paris, France.
- 89 ⁴³Department of Women's and Children's Health, Karolinska Institute, Karolinska University
90 Hospital, Stockholm, Sweden.
- 91 ⁴⁴Suzhou Institute for Systems Biology, Chinese Academy of Medical Sciences, Suzhou,
92 China.
- 93 ⁴⁵Medizinische Klinik, Johannes Gutenberg University Mainz, Germany.
- 94 ⁴⁶Division of Infection and Immunity, University College London, London, UK.
- 95 ⁴⁷NIHR Biomedical Research Centre, University College London Hospitals, London, UK.
- 96

97 *Corresponding author:*

98 Laurence ZITVOGEL, MD, PhD, Full Professor

99 University Paris Saclay,

100 Gustave Roussy Cancer Center,

101 114 rue Edouard Vaillant,

102 94805 Villejuif Cedex, France

103 Telephone: +33 1 42 11 50 41

104 E-mail: laurence.zitvogel@gustaveroussy.fr

105

106 Keywords: TH2/TH1 paradigm, cancer, COVID-19, S1-RBD, viral variants, T cell memory

107 **Abstract**

108 Optimal vaccination and immunotherapy against coronavirus disease COVID-19 relies on the
109 in-depth comprehension of immune responses determining the individual susceptibility to be
110 infected by SARS-CoV-2 and to develop severe disease. We characterized the polarity and
111 specificity of circulating SARS-CoV-2-specific T cell responses against whole virus lysates or
112 186 unique peptides derived from the SARS-CoV-2 or SARS-CoV-1 ORFome on 296 cancer-
113 bearing and 86 cancer-free individuals who were either from the pre-COVID-19 era (67
114 individuals) or contemporary COVID-19-free (237 individuals) or who developed COVID-19
115 (78 individuals) in 2020/21. The ratio between the prototypic T helper 1 (TH1) cytokine,
116 interleukin-2, and the prototypic T helper 2 (TH2) cytokine, interleukin-5 (IL-5), released from
117 SARS-CoV-2-specific memory T cells measured in early 2020, among SARS-CoV-2-negative
118 persons, was associated with the susceptibility of these individuals to develop PCR-detectable
119 SARS-CoV-2 infection in late 2020 or 2021. Of note, T cells from individuals who recovered
120 after SARS-CoV-2 re-infection spontaneously produced elevated levels of IL-5 and secreted
121 the immunosuppressive TH2 cytokine interleukin-10 in response to SARS-CoV-2 lysate,
122 suggesting that TH2 responses to SARS-CoV-2 are inadequate. Moreover, individuals
123 susceptible to SARS-CoV-2 infection exhibited a deficit in the TH1 peptide repertoire affecting
124 the highly mutated receptor binding domain (RBD) amino acids (331-525) of the spike protein.
125 Finally, current vaccines successfully triggered anti-RBD specific TH1 responses in 88%
126 healthy subjects that were negative prior to immunization. These findings indicate that COVID-
127 19 protection relies on TH1 cell immunity against SARS-CoV-2 S1-RBD which in turn likely
128 drives the phylogenetic escape of the virus. The next generation of COVID-19 vaccines should
129 elicit high-avidity TH1 (rather than TH2)-like T cell responses against the RBD domain of
130 current and emerging viral variants.

131

132

133 **Introduction**

134

135 The emergence and spread of severe acute respiratory syndrome coronavirus-2 (SARS-
136 CoV-2), the causative agent of coronavirus disease 2019, have resulted in devastating
137 morbidities and socioeconomic disruption. The development of community protective
138 immunity relies on long-term B and T cell memory responses to SARS-CoV-2. This can be
139 achieved through viral infection [1] or by vaccination [2-4]. Reports on rapidly decreasing

140 spike- and nucleocapsid-specific antibody titers post-COVID-19 infection [5] or reduced
141 neutralizing capacity of vaccine-induced antibodies against viral escape variants compared to
142 the ancestral SARS-CoV-2 strain [6, 7] have shed doubts on the importance of humoral
143 immunity as a standalone response. In contrast, T cell immunity was identified as an important
144 determinant of recovery and long-term protection against SARS-CoV-1, even 17 years after
145 infection [8-11].

146 The TH1 versus TH2 concept suggests that modulation of the relative contribution of
147 TH1 or TH2 cytokines regulates the balance between immune protection against microbes and
148 immunopathology [12-14]. TH1 cells (as well as cytotoxic T cells with a similar cytokine
149 pattern referred to as TC1 cells) produce IFN γ , IL-2, and TNF β , promote macrophage
150 activation, antibody-dependent cell cytotoxicity, delayed type hypersensitivity, and opsonizing
151 and complement-fixing IgG2a antibody production [12]. Therefore, TH1/TC1 cells drive the
152 phagocyte-dependent host response and are pivotal for antiviral responses [13, 14]. In contrast,
153 TH2 (and TC2) cells produce IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13, providing optimal help
154 for both humoral responses and mucosal immunity, through the production of mast cell and
155 eosinophil growth and differentiation factors, thus contributing to antiparasitic and allergic
156 reactions. Naïve T cell differentiation to distinct TH fates is guided by inputs integrated from
157 TCR affinity, CD25 expression, costimulatory molecules, and innate cell-derived cytokines
158 [15].

159 SARS-CoV-2-specific T cell immunity plays a key role during acute COVID-19, and
160 up to eight months after convalescence [16-20]. Indeed, functional T cell responses remain
161 increased in both frequency and intensity up to six months post-infection [5]. They are mainly
162 directed against spike, membrane and nucleocapsid proteins, and have been studied in greater
163 detail by single cell sequencing in a limited number of patients. Memory TH1/TC1 T cells
164 specific for SARS-CoV-2 and follicular T helper cells (TFH) cells have been detected in mild
165 cases [21]. However, cases of reinfection have been reported [22] raising questions on the
166 clinical significance of T cell polarization and peptide repertoire specificities against current
167 viral variants. Moreover, pioneering reports suggest that, before SARS-CoV-2 became
168 prevalent (i.e., before 2020), some individuals exhibit immune responses, mainly among CD4⁺
169 T cells, against SARS-CoV-1 nucleocapsid (NC) and ORF1a/b, or common cold coronaviruses
170 (CCC) spike and nucleocapsid proteins that are cross-reactive with SARS-CoV-2 [9, 23, 24,
171 80]. However, the relevance of CCC or SARS-CoV-1-specific memory T cells for effective
172 protection against the current pandemic remains questionable [21, 25].

173 In the present report, we studied SARS-CoV-2 –specific T cell responses in 382 cancer-
174 bearing or cancer-free subjects, and prospectively followed up 227 COVID-free individuals to
175 understand which T cell polarity and peptide repertoire may convey resistance to COVID-19.
176 We found that a SARS-CoV-2-specific IL-2/IL-5 lymphokine ratio <1 conferred susceptibility
177 to COVID-19 infection or re-infection, coinciding with defective TH1 recognition of the
178 receptor binding domain (RBD) of the spike protein, likely affecting viral evolution by selecting
179 for new antigenic variants.

180

181 **Results**

182

183 **Effector and memory T cell responses against coronaviruses during COVID-19 infection**

184

185 We conducted a cross-sectional analysis of the functional T cell responses across several
186 cohorts of healthy individuals and cancer patients enrolled in various prospective studies (Table
187 S1-S2). First, an epidemiological observational study (Figure 1A) aimed at defining the
188 incidence, prevalence, and severity of COVID-19 in cancer patients, opened during the first
189 surge of the pandemic at Gustave Roussy [26]. While the majority of the 227 enrolled cancer
190 patients stayed COVID-19-free, we could analyze T cell responses during the acute phase of
191 SARS-COV-2 infection (n=24) or during convalescence post-COVID-19 (n=28). All the other
192 "unexposed" (COVID-19-negative) cancer patients were analyzed anytime between mid-March
193 and September 2020 (Table S1, Figure 1A). In parallel, we analyzed 22 cancer-free, COVID-
194 19-free healthy volunteers (HV) from 15 distinct families at the same time as their family
195 members were in convalescent phase for COVID-19 (n=26) (Figure 2A, Table S3). A third
196 cohort of 67 individuals from the pre-COVID-19 era (leukocytes frozen between 1999 and
197 2018) were either HV from the blood bank (n=38) or cancer patients (n=29) recruited in the
198 context of clinical trials [27-30] (Table S1, Figure 1A).

199 T cell responses directed against viral lysates from the historic SARS-CoV-2 strain
200 IHUMI846 (CoV-2) isolated in early 2020 or two endemic common cold coronaviruses (CCC),
201 OC43 and 229E, were evaluated by an *in vitro* stimulation assay (IVS). As outlined in Figure
202 1B, in a first step, autologous dendritic cells (DC) were differentiated from monocytes for 72hrs
203 in GM-CSF+IFN α 2b. DC were spinoculated with viral particles from heat-inactivated viral
204 lysates and activated with LPS in a second step. Peripheral blood lymphocytes (PBL) kept in
205 low-dose IL-2 during this first step were then stimulated for 48hrs by activated DC after
206 removal of LPS (Figure 1B). The specific viral lysates were compared to supernatants from cell

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

207 lines permissive for viral replication (such as Vero E6 for SARS-CoV-2, HCT8 for OC43,
208 MRC5 for 229E). Negative controls were unloaded DC/PBL cell cocultures, while positive
209 controls were PBL stimulated with anti-CD3/anti-CD28 -coated beads. The cytokines
210 accumulating in the supernatants were analyzed by means of a 12-plex flow cytometry-based
211 bead assay (Figure S1A). In this cross-presentation assay, SARS-CoV-2-related IFN γ or IL-2
212 secretions from PBL depended on MHC class I and MHC class II molecules, as shown using
213 specific neutralizing antibodies (Figure S1B). We calculated the ratio of cytokine release by
214 dividing interleukin concentrations following exposure to viral lysates by those obtained with
215 the respective control supernatants, to ascribe the specificity of the reactivity to SARS-CoV-2
216 or to CCC antigens for each subject.

217 First, we characterized the intensity and the quality of PBL responses elicited at the
218 acute phase of SARS-CoV-2 infection (day of symptom onset and/or first positive qPCR of the
219 oropharyngeal swab and/or serology), between mid-March and mid-May 2020 in 24
220 interpretable tests performed on COVID-19⁺ subjects compared to a cohort of 304 controls
221 (Table S2). Robust SARS-CoV-2 specific IL-2 and IFN γ release, most likely caused by
222 TH1/TC1 cells, and the secretion of IL-4, IL-5 and IL-10, most likely mediated by TH2/TC2
223 effector T cells, were detectable, and were dominated by IL-2 and IL-5, respectively (Figure
224 1C, Figure 1D). An antiviral response, characterized by type 1 IFN release, was also prevalent
225 (Figure S1C), as previously detected by single cell transcriptomics in the subset of transitional
226 memory CD4⁺ T cells [21]. Of note, COVID-19 infection did not reactivate CCC-specific T
227 cell responses (Figure 1D, Figure S2A). Interestingly, the systemic T cell tone was shifted
228 towards an inflammatory TH2 profile during the acute phase of the infection, as suggested by
229 increased IL-5, IL-6, TNF α , and IL-17 secretion following TCR cross-linking in COVID-19
230 patients compared with individuals without COVID-19 (Figure 1D, Figure S1C).

231 We next examined the polarization of SARS-CoV-2-specific memory T cell responses
232 between May and September 2020 in 54 convalescent COVID-19 individuals (median time
233 lapse between PCR negative and T cell assay: 85 days, range: 13-106 days) compared with
234 contemporary controls (Figure 1A, Figure 1C, Figure 1D, Figure S2, Table S2). A dominant
235 SARS-CoV-2-specific memory TH1 response (resulting in the secretion of IFN γ , IL-2 and
236 TNF α) prevailed in most convalescent subjects within the next 2-3 months after acute infection
237 (Figure 1D). Of note, SARS-CoV-2 specific IL-2 release at recovery correlated with an increase
238 in the frequency of circulating non-activated TFH cells (Figure S1D). In addition, SARS-CoV-
239 2 specific IL-2 secretion was the only parameter correlating with anti-SARS-CoV-2

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

240 nucleocapsid (NC) antibody titers (reported to be stable for 8 months [5]) but not with IgG and
241 IgA antibodies targeting the S1 domain of the SARS-CoV-2 spike protein including the RBD
242 (Figure 1E-F and not shown).

243 More than 30% convalescent COVID-19 individuals displayed polyfunctional T cell
244 responses defined by at least 2 cytokines with a secretion ratio >1.5 (Figure S2A-B). Memory
245 TH1 (IL-2, IFN γ) responses were comparable in both healthy and cancer subsets of COVID-19
246 positive individuals (Figure S2B-C). As previously described [21, 23, 24, 31, 32], contemporary
247 COVID-19 negative subjects also harbored significant SARS-CoV-2 specific-TH1/TC1
248 memory responses that appear to pre-exist in cancer patients and healthy individuals whose
249 blood was drawn in the pre-COVID-19 era, including prior to outbreaks of SARS-CoV-1 and
250 MERS (Figure S2B-C). The unsupervised hierarchical clustering considering 12 cytokines
251 monitored in 358 subjects did not segregate pre-COVID-19 from contemporary unexposed
252 individuals nor convalescent patients (Figure S2A).

253 Hence, while polyfunctional T cell responses dominated by IL-2 and IL-5 were elicited
254 during the acute phase of COVID-19, after convalescence, recirculating memory T cells
255 exhibited a TH1/TC1 profile in about 70% of COVID-19 patients, correlating with anti-SARS-
256 CoV-2 NC antibody titers.

257

258 **Clinical relevance of the IL-2/IL-5 ratio to predict COVID-19 infection**

259

260 We next determined the clinical significance of these memory T cell responses monitored in
261 unexposed individuals during the first surge of COVID-19 (mid-March to mid-May 2020) to
262 decipher the nature of memory T cells contributing to susceptibility or resistance to the
263 successive surges of this viral pandemic in fall 2020 and winter 2021. We phoned 229 patients
264 to discover that 22 individuals had developed COVID-19 infections (diagnosed by qPCR or
265 serology) with different degrees of severity according to WHO criteria (Table S1, Figure 2A,
266 Table S4). Indeed, about one third of the initially COVID-19-free individuals became contact
267 cases ($n=70$) and 29% among these contact cases were diagnosed with COVID-19 infection by
268 specific RT-qPCR or serology ($n= 22$, Figure 2B, Table S4). The unsupervised hierarchical
269 clustering of the T cell secretory profiles in these 70 individuals failed to correctly segregate
270 resistant (contact) from susceptible (infected) cases (Figure S3A). In addition, the
271 polyfunctionality of T cell responses failed to segregate the two categories of individuals
272 (Figure 2C, Figure S4B). However, two lymphokines, IL-2 and IL-5, secreted by memory T
273 cells responding to SARS-CoV-2 correlated with resistance and susceptibility to SARS-CoV-

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

274 2, respectively (Figure 2D-E). Indeed, the levels of IL-2 in the recall response and the
275 proportions of individuals exhibiting IL-2 polarized T cell memory responses were both
276 associated with resistance to COVID-19 (Figure 2D, $p=0.01$, two-sided Wilcoxon-Mann-
277 Whitney test, Figure 2E, $p=0.049$, Fisher exact test). In contrast, IL-5 levels in recall responses
278 were associated with increased susceptibility to COVID-19 (Figure 2D, $p=0.057$, two-sided
279 Wilcoxon-Mann-Whitney test). Resistant individuals harbored a coordinated SARS-CoV-2
280 specific-TH1 response (IFN γ , TNF α) in mid-March to mid-May 2020, while subjects
281 susceptible to COVID-19 exhibited inflammatory TH9/TH17-like networks (Figure S4C-D).
282 These findings are reminiscent of data segregating asymptomatic or mild from severe diseases
283 [33, 34]. For this reason, we henceforth analyzed the clinical significance of the ratio between
284 SARS-CoV2-specific IL-2 and IL-5 release. Indeed, the IL-2/IL-5 recall response ratio was
285 significantly higher in cancer patients who were SARS-CoV-2-resistant (Figure 2F) and in
286 convalescent patients (Figure S4A). The vast majority (16 out of 19) of cancer patients doomed
287 to be infected with SARS-CoV-2 harbored an IL-2/IL-5 ratio ≤ 1 , with the two severe COVID-
288 19 cases exhibiting an IL-2/IL-5 ratio < 10 (Figure S4B). In contrast, CCC-specific T cell
289 reactivities did not allow to discriminate susceptible from resistant individuals (Figure 2G),
290 although IL-5 stood out as the strongest correlate between SARS-CoV-2 and CCC-specific T
291 cell responses among 156 individuals with no correlation between SARS-CoV-2 and OC43-
292 specific IL-2 secretion (Figure 2H). Reinforcing this notion, titers of IgG antibodies directed
293 against the spike of the seasonal betacoronaviruses OC43 and HKU1 (but not the
294 alphacoronavirus 229E and NL63) were higher in individuals susceptible to SARS-CoV2
295 compared to resistant individuals (Figure 2I and not shown).

296 The SARS-CoV2-specific IL-2/IL-5 recall response ratio was also clinically significant
297 in the cohort of cancer-free individuals that were locked down together with their COVID-19-
298 positive family members (Figure 2A, Table S3, Figure S4D). Individuals who did not get
299 infected harbored IL-2/IL-5 ratios > 1 reaching mean values comparable to those achieved in
300 convalescent individuals (Figure 2F, Figure S4A) at higher frequencies than the overall
301 population (Figure S4C).

302 We next compared the immunogenicity of the lysates derived from the original SARS-
303 CoV-2 strain (IHUMI846) with that of the Danish (IHUMI2096, 20A.EU2, B.1.367, GH) and
304 North African (IHUMI2514, 20C, B.1.160, GH) strains isolated at the end of 2020 [35]. Of
305 note, T cells lost their capacity to produce IL-2 in response to the IHUMI2096 and IHUMI2514
306 viral variants while IL-17 release tended to increase ($p= 0.0857$, Figure S5A).

307 Given that 15-20% of convalescent individuals mounted a TH2/TC2 memory response
308 to SARS-CoV-2 (Figure S2A), we wondered whether these individuals could be at higher risk
309 to get re-infected by SARS-CoV-2 variants. Hence, we analyzed PBMCs in a series of
310 individuals (n=12) who were diagnosed with COVID-19 during the first surge of the SARS-
311 CoV-2 pandemic and then were re-infected with a viral variant prevailing during the later
312 outbreak occurring in fall 2020 or winter 2021, comparing them to health care workers who
313 were multi-exposed cases with multiple negative oropharyngeal SARS-CoV-2 -specific PCR
314 assays (n=17) (Table S5, Figure 2J, left panel). Surprisingly, monocytes could be differentiated
315 into dendritic cells only in 4 re-infected patients. Unstimulated PBL from re-infected and re-
316 convalescent subjects spontaneously secreted much higher levels of IL-5 than did PBL from
317 multi-exposed cases, reaching similar ranges as those obtained after TCR crosslinking (Figure
318 2J, middle panel). After specific re-stimulation with SARS-CoV-2 lysates, IL-10 was markedly
319 increased in recall responses from re-infected but not multi-exposed cases (Figure 2J, right
320 panel) and IL-2 was undetectable (Figure S5B). In this small cohort of multi-exposed
321 individuals, the recognition pattern of the United Kingdom (UK) (IHUMI3076, B.1.1.7), South
322 Africa (IHUMI3147, B.1.351) and Brazil (IHUMI3191, P.1) [35] strains were quite variable,
323 some individuals losing the TH1/TC1 or acquiring a TH2/TC2 profile, depending on the strain
324 (Figure S5C).

325 We conclude that the TH1/TC1 *versus* TH2/TC2 polarity of SARS-CoV-2 specific-
326 memory T cell responses is associated with effective clinical protection against infection, an
327 IL-2/IL-5 ratio >1 indicating resistance to the COVID-19.

328

329

330 **Defects in the TH1/TC1 response against the SARS-CoV-2 RBD of spike glycoprotein in** 331 **susceptible individuals**

332

333 In hosts affected by viral infections or cancer, the breadth of T cell epitope recognition is a
334 prerequisite for protective immunity [36-38]. We analyzed the diversity of SARS-CoV-2 T cell
335 responses by single peptide mapping using 186 peptides with 9 to 51 amino acids corresponding
336 to 146 non-overlapping or poorly overlapping epitopes of the SARS-CoV-2 ORFeome (among
337 which 25 epitopes were shared with SARS-CoV-1), encompassing membrane, nucleocapsid,
338 spike, ORF3a, ORF8 and ORF10 proteins, plus 41 epitopes covering the SARS-CoV-1
339 ORFeome of immunological relevance (among which 8 epitopes were shared with SARS-CoV-
340 2), as well as a series of positive controls, namely epitopes from Influenza virus, Epstein Barr

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

341 virus (EBV), Cytomegalovirus (CMV), phytohemagglutinin (PHA), and anti-CD3 ϵ (OKT3)
342 antibody. IFN γ responses against these 186 peptides were evaluated in 164 individuals (123
343 unexposed individuals, 25 convalescent COVID-19-positive patients, 16 re-infected patients,
344 see Table S6). To enable the detection of low-frequency SARS-CoV-2 peptide-specific T cells,
345 we used an *in vitro* 7 day-long, IL-2+IL-15 enriched IVS assay in the presence of each
346 individual peptide in duplicates (Figure 3A). We chose to monitor IFN γ , a proxy for TH1/TC1
347 responses, as opposed to IL-2, in the 7 day- coculture supernatants by ELISA because
348 recombinant human IL-2 was already added to the IVS assay (Figure 3A). The overall
349 recognition patterns of these peptides across various patient populations, and their individual
350 frequencies are detailed in Figure 3B, and Figure S6-S7. About 10% convalescent individuals
351 recognized more than 15% of our peptide selection within the SARS-CoV-2 ORFeome (Figure
352 S6 inset). T cell responses in unexposed patients, in particular in the pre-COVID-19 era,
353 covered large specificities, as suggested by previous reports [9, 21, 24] (Figure 3C, right panel
354 and Figure S6). In accord with the literature [9, 24], the immune response of convalescent
355 COVID-19 patients was mainly directed against spike, membrane, and nucleocapsid (NC) and,
356 to a lower extent, against ORF3a, ORF8, and ORF10 (Figure 3B, 3D left panel). The breadth
357 of the peptide recognition coverage was not significantly reduced in cancer patients compared
358 with others (Figure 3B, 3C left panel). In a limited number of individuals, we measured not
359 only IFN γ but also IL-5, IL-9 and IL-17 by ELISA. The recognition profile specific to the spike
360 (and more specifically the RBD) as well as ORF8 was more geared toward TH1/TC1 (IFN γ)
361 than TH9 or TH2 (IL-9 or IL-5 production respectively) (Figure S8A-C). The membrane- and
362 NC-specific repertoire was strongly TH17 oriented (Figure S8B).

363
364 Using logistic regression analyses, we determined the TH1/TC1 peptide recognition
365 fingerprint significantly associated with each patient category (Figure S9). The hallmark
366 repertoire of the pre-COVID-19 era consisted in a stretch of peptides covering part of the
367 SARS-CoV-1 genome (spike, membrane, ORF3a, NC), some peptide residues sharing high or
368 complete homology with SARS-CoV-2, as well as numerous ORF8 sequences (Table S6). Of
369 note, the recognition pattern of these SARS-CoV-1 epitopes highly correlated with responses
370 directed against ORF8 peptides (not shown). In contrast, the COVID-19-associated blueprint
371 encompassed many nucleocapsid peptides (NC_1 (residues 1-15), NC_6-7 (residues 76-105,
372 NC_8 (residues 106-120) sharing 93% and 100% homology with OC43 and HKU1,
373 respectively, the HLA-A2- restricted nonamer (RLNQLESKV) NC_226-234 from SARS-

374 CoV-1 (sharing high structural homology with the SARS-CoV2 epitope RLNQLESKM) and
375 another SARS-CoV-1 NC nonamer peptide (NC_345-361), three peptides residing in ORF8,
376 two epitopes belonging to the RBD region ("SPIKE29") found at high frequency across subjects
377 (23.5%), as well as a peptide from the C terminal portion of spike ("SPIKE84", residues 1246-
378 1260) (Figure S9A). Cancer patients tended to lack some specificities, yet with no prototypical
379 signature (Figure S9A).

380 Next, we investigated the ORFeome peptide repertoire associated with SARS-CoV-2-
381 specific IL-2 memory responses in 118 unexposed individuals by means of linear regression
382 analysis (Figure 4A, left panel). Among the 9 peptides associated with a positive contribution
383 to IL-2 secretion, one nonamer (KLPDDFMGCV in SARS-CoV-1 genome and
384 KLPDDFTGCV in the SARS-CoV-2 genome) resided in the RBD region that constitutes the
385 binding site for its cellular receptor angiotensin-converting enzyme 2 (ACE2) [39] while,
386 conversely among the 13 peptides associated with a hole in the TH1 response, 5 resided within
387 the RBD of the spike glycoprotein. More specifically, there was a statistically significant
388 enrichment of RBD-related peptides within this TH1/TC1 hole (Figure 4A, right panel).

389 In order to validate the clinical significance of the TH1/TC1 repertoire hole and the
390 assumption that a defect in the TH1/TC1 recognition pattern of the RBD sequence could be a
391 risk factor for COVID-19, we calculated the number of positive peptides selected from the RBD
392 region spanning aminoacid 331-525 residues (called "SPIKE23" to "SPIKE35" in Table S6), in
393 each of the 83 individuals who were comprehensively explored in the peptide-based IVS assay,
394 37 resistant (contact) individuals, 14 infected persons (susceptible) as well as 32 controls
395 (unexposed lockdown and/or unknown) using the IFN γ ELISA (Table S1). While susceptible
396 individuals exhibited a significant defect in the RBD-related TH1/TC1 repertoire (Figure 4B),
397 up to 25% of the resistant individuals harbored robust TH1/TC1 responses to the 331-525
398 aminoacid residues of RBD (Figure 4B, $p=0.049$, Fisher exact test). Again, the RBD-specific
399 TH1/TC1 responses were almost undetectable in patients who got infected twice with SARS-
400 CoV-2 (Table S5), while they could be measured in 50% convalescent COVID-19 patients
401 (Figure 4C, $p=0.011$, Fisher exact test) in accordance with a recent report highlighting the
402 immunodominance of the S346-365 region (corresponding to our "SPIKE24" epitope) in
403 convalescent individuals [40]. Such S1-RBD-specific TH1 responses pre-existed in the pre-
404 COVID-19 era at the same frequency in cancer or cancer-free individuals (Figure 4D). T cell
405 responses directed against S1-RBD peptides were evaluated for both IL-5 and IFN γ secretions
406 in 36 patients. They almost exclusively exhibited a TH1 pattern (in 10/36 cases), with only 3/36
407 individuals harboring a TH2 profile (Table S7). Of note, there was a robust consistency and

408 concordance of the polarization status of patients between the two (cross-priming and peptide-
409 based) IVS assays (McNemar test, $p = p.val = 2.2e-16$ comparing SARS-CoV-2 or peptide-
410 specific IL-2 and IFN γ release, McNemar test, $p = p.val = 2.2e-16$ comparing SARS-CoV-2 or
411 peptide-specific IFN γ release, $p.val < 1e-16$).

412 We performed immunoinformatic-based prediction analyses of S1-RBD peptide
413 binding affinities to MHC class I and class II molecules using the NetMHCpan algorithm. This
414 approach revealed strong binding affinities to MHC class I HLA-A, -B and -C alleles for the
415 RBD epitopes "SPIKE25" (residues 361_375), "SPIKE27" (residues 391-405), "SPIKE31"
416 (residues 451-465). In contrast, "SPIKE33" (residues 481_495) was predicted to have a low or
417 absent affinity for HLA-B and HLA-C alleles, respectively (Table S8a). Only "SPIKE24",
418 "SPIKE25" and "SPIKE31" were predicted to bind with a high affinity to HLA-DR alleles (Table
419 S8b) as already reported for the immunodominant S346-365 region [40].

420 In accordance with the immunodominance of S1-RBD, the other signatures indicated
421 by our logistic regression analysis (Figure S9A), namely the convalescent or the pre-COVID-
422 19 era -related blueprints were not significantly associated with COVID-19 resistance (Figure
423 S9B-C).

424 Given that immunoselection may drive antigenic drift of viruses as well as the evolution
425 of viral phylogeny, we analyzed the coincidence of hot spot mutations in the SARS-CoV-2
426 ORFeome [41] with T cell memory patterns of clinical significance (Table S9). Of note,
427 significantly higher mutation frequencies were detected within the S1-RBD-specific TH1
428 response (62%) compared with other regions of the SARS-CoV2 orfeome (26%) (Odd Ratio =
429 0.21, 95% confidence interval [0.06; 0.68], $p = 0.01$, Figure 4E).

430 During the course of this study, two SARS-CoV-2 mRNA vaccines were approved by
431 FDA and EMA based on reports that they prevent COVID-19 infection with an efficacy of
432 >90% [3]. Using a simple whole blood stimulation assay allowing the detection of IFN γ -
433 producing anti-viral T cells following peptide stimulation within 18 hours [42], we analyzed
434 RBD-specific T cell reactivities before and after dual vaccination with BNT162b2 mRNA
435 (BioNTech/Pfizer) in 70 unexposed health care workers (HCW) and 14 COVID-19
436 convalescent HCW (Table S10). The vast majority (approximately 90%) of naive vaccinees
437 mounted robust RBD-specific TH1/TC1 cell responses after 2 immunizations (Figure 4F).

438 Hence, our findings suggest that defects in the TH1 repertoire affecting the recognition
439 of SARS-CoV-2 S1-RBD are associated with susceptibility to infection or re-infection by

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

440 SARS-CoV-2. This antigenic region appears to mutate more than other regions of the SARS-
441 CoV-2 orfeome, perhaps as a result of an immune system-mediated evolutionary pressure.

442

443

444 **Discussion**

445

446 Here, we unravel the first *prospective* correlation between preexisting (before the first
447 surge) SARS-CoV-2-specific TH2/TC2 immune responses and susceptibility to infection with
448 SARS-CoV-2 or re-infection with viral variants. Both in cancer patients and cancer-free
449 subjects, the best immunological correlate with future SARS-CoV-2 infection was
450 undistinguishably a recall response characterized by a low ratio of TH1/TH2 lymphokines (and
451 more precisely an IL-2/IL-5 ratio <1) secreted upon exposure to the original SARS-CoV-2 viral
452 strain. This recall response coincided with a hole within the TH1/TC1 cell repertoire affecting
453 the RBD of the spike protein. Moreover, in a small series of re-infected individuals, maladaptive
454 anti-SARS-CoV-2 responses were characterized by elevated baseline TH2 responses
455 (spontaneous IL-5 release from PBL) and IL-10-centered recall responses. Finally, vaccinees
456 immunized with a clinically approved mRNA encoding the spike protein mounted a robust
457 RBD-specific TH1/TC1 response, that may account for immune protection.

458 Reportedly, CD4⁺ TH1 and TH2 responses are induced during the primary phase of
459 viral infection, and both TH1 and TH2 can generate an anamnestic response upon rechallenge
460 with the same virus [43]. Survivors from SARS-CoV-1 infection developed polyfunctional T
461 cells producing TH1 cytokines and long-term CD8⁺ T cell responses as late as 11 years post-
462 infection [9]. The TH1 cytokine IL-2 (which correlated with circulating non-activated TFH
463 cells in convalescent patients in our study) was the pivotal factor allowing us to distinguish
464 susceptible from resistant individuals. Signaling via the high-affinity IL-2 receptor (which
465 requires CD25/IL-2R α expression) favors the generation of CXCR5⁻ T effector cells, and this
466 is associated with TH1 responses sustained by the transcription factor TBX21. Moreover, the
467 development of IFN γ producing effector memory T cells depends upon CD25 [15].
468 Accordingly, upon infection with lymphocytic choriomeningitis (LCMV), CD25-deficient
469 CD4⁺ T cells largely fail to form IFN γ producing T effector cells in secondary lymphoid organs
470 and to generate lung tissue resident memory T cells [44].

471 In contrast, increased TH2 cytokine release correlated with poor outcome in patients, a
472 finding corroborated in mouse studies of SARS-CoV-1 [45, 46]. During SARS-CoV-2
473 infection, TH2-associated blood markers, such as eosinophilia and circulating IL-5, IL-33,

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

474 eotaxin-2 and eotaxin-3 correlated with COVID-19 severity, contrasting with the fact that
475 CD4⁺ and CD8⁺ T cells from COVID-19 patients secrete comparable amounts of IFN γ in
476 moderate and severe disease [47].

477 What cellular cues may influence TH2 differentiation or maintenance? Distinct
478 dendritic cell subsets could specifically induce TH2 immunity, while limiting TFH responses
479 and humoral immunity [48-50]. Indeed, preferential trans-vasation of blood-born cDC2 (CD1c⁺
480 DC) into the bronchoalveolar fluid was described for severe COVID-19 [51], and TH1/TH2
481 polarization is not only achieved during the priming response in lymphoid organs but is largely
482 driven by the preferential expansion of either TH1 or TH2 cells in non-lymphoid tissues [52].
483 Various cell types located in peripheral tissues can impact T cell fate [53]. In the lungs of severe
484 COVID-19 patients, a clonal expansion of IL-17A/F and GM-CSF producing TRM-like CD4⁺
485 T cells persisted even after viral clearance [34]. Our findings point to some correlative links
486 between IL-5 and GM-CSF in recall responses from individuals susceptible to COVID-19.
487 While IL-7 secreting stromal cells may promote survival of TH2 memory cells within lung
488 tertiary lymphoid structures [54, 55], it remains unclear to which extent local (oropharyngeal
489 or pulmonary) cues might influence the maintenance of SARS-CoV-2 specific or cross-reactive
490 TH2 responses.

491 TCR signaling plays a major role in CD4⁺ polarization and can vary according to the
492 TCR affinity, the amount of peptide/MHC-II complexes perceived by a TCR, or the length of
493 time a T cell spends proofreading peptide/MHC-II complexes [15]. Of note, the RBD-specific
494 TH1/TC1 responses against regions 361_375 and 391_405 of spike exhibited robust binding
495 capacities across all MHC class I alleles. Several authors reported cross-reactivities between
496 CCC and SARS-CoV2 [9, 20, 23, 24, 31, 32, 56, 57]. However, such cross-reactive T cells may
497 turn out to be harmful with respect to clinical correlations [58-63]. Indeed, according to one
498 report [21], preexisting CCC-specific memory CD4⁺ T cells exhibit low TCR avidity in almost
499 all unexposed individuals, and are strongly expanded in severe COVID-19 but not in mild cases.
500 Moreover, CCC/SARS-CoV-2-cross-reactive T cell clones shared among convalescent and
501 infected individuals harbored lower functional avidity than non-cross-reactive clones,
502 suggesting antigenic imprinting of the TCR repertoire by previous exposure to CCC [25, 82].
503 Of note, these spike-specific cross-reactive CD4⁺ T cells might not only re-expand during
504 infection but also following vaccination. In line with this possibility, we detected a strong
505 positive correlation between CCC and SARS-CoV2-specific IL-5 release by memory T cells in
506 all unexposed individuals. Moreover, CCC-specific IgG titers were higher in susceptible
507 compared to resistant individuals. Finally, the SARS-CoV-1 and ORF8-specific T cell

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

508 repertoire prevailing in the pre-COVID-19 era failed to be clinically relevant for the avoidance
509 of COVID-19 and such a repertoire was frequently detected in re-infected individuals during
510 their convalescence phase. Hence, we cannot rule out the possibility that a preexisting TH2
511 immunity, for instance directed against sequences shared by sarbecoviruses [9] could increase
512 the susceptibility to, and severity of, SARS-CoV-2 infection [45-47].

513
514 The landscape of prevalence and immunodominance of SARS-CoV-2 epitopes - supposedly
515 associated with protection during the acute phase - has been thoroughly investigated [64]. Using
516 40-mer peptide pools covering regions of membrane, nucleocapsid, ORF3a, ORF7/8, and spike
517 proteins, Tan et al. observed a statistically significant correlation between the early appearance
518 of SARS-CoV-2 peptide-reactive cells and shorter duration of infection [65]. However, viruses
519 employ numerous strategies to evade CD8⁺ T cell immune responses [66]. Our data obtained
520 in COVID-19-free individuals who remained resistant to overt infection despite exposure to the
521 virus strongly support the immunological and clinical relevance of memory TH1/TC1
522 responses directed against the spike S1-RBD region. An immune-driven selection process of
523 viral phylogeny can occur [67]. Early (but transient) induction of ORF7/8-specific TH1 cell
524 immune responses as well as antibody responses against ORF8 have already been reported
525 during the acute phase of COVID-19 in small numbers of patients. Some arguments plead for
526 the biological significance of ORF8-specific T cell immunity in viral control. Indeed, a 382-
527 nucleotide deletion that truncates ORF7b and ORF8, culminating in the loss of ORF8
528 transcription, and conferring mild forms of infections [68] has been reported [69]. However,
529 our data do not support the clinical relevance of ORF8-specific immune responses.

530 There is growing evidence of the links between mutations within the SARS-CoV-2
531 spike protein and the evasion of neutralizing antibody responses [70, 71]. Single
532 nonsynonymous mutations in SARS-CoV-2 can theoretically subvert the immune response to
533 CTL epitopes as well [72]. These studies suggested that immune selection may shape the
534 mutational landscape of CD8⁺ T cell epitopes. Our data fuel the theory that i) robust TH1
535 memory immune responses against RBD might be important in restraining viral infection, thus
536 exerting a selective pressure on the virus, obliging it to generate escape variants by mutation of
537 RBD, ii) preexisting TH2 antiviral responses might not only be incapable of eliminating SARS-
538 CoV-2-infected cells but actually favor (re-)infection with SARS-CoV-2, ultimately increasing
539 the viral reservoir, thus favoring the emergence of viral variants.

540

541 Our work may have important consequences for the design of next-generation vaccines
542 against COVID-19. Immunization strategies should aim at triggering SARS-CoV-2 specific
543 TH1/TC1 (rather than TH2/TC2) responses. The efficacy of cellular immune response relies on
544 three components, (i) the antigen, (ii) the adjuvant and (iii) the dynamics of viral evolution [73].
545 Immunization with inactivated SARS-CoV-1 or with the whole spike (S) protein, caused
546 eosinophilic infiltration following viral re-exposure in mice [74, 75]. In contrast, at least in the
547 case of SARS-CoV-1, immunization with RBD induced neutralizing antibodies in the absence
548 of a TH2/TC2 response [76]. Vaccine adjuvants can stimulate TH1/TC1-favorable innate
549 immunity [77, 82], as this is the case for multiple viral vectors, virus-like particles and mRNA
550 containing nanoparticles. Finally, virus adaptation to the host has to be outcompeted. One might
551 infer from our data that the currently protective immunodominant regions generating a
552 TH1/TC1 profile may be the focus of the future antigenic drift of SARS-CoV-2.

553 Community-protective immunity can affect RNA virus evolution by selecting for new
554 antigenic variants on the scale of years, as exemplified by the need for annual evaluation of
555 influenza vaccines [78]. It is likely that pandemic SARS-CoV-2 evolution bears similarities
556 with human influenza A virus evolution including accumulation of adaptive changes in the
557 receptor binding domain (RBD), in which case vaccines would have to be updated regularly
558 [78]. Therefore, to win the race against current virus strains and emerging variants, an expedited
559 world-wide vaccination rollout ensuring an immunization *en masse* against relevant epitopes
560 (and in particular the entire RBD region of the variants from Brazil, India, and South Africa)
561 with vaccine formulations ensuring TH1/TC1 (rather than TH2/TC2) responses should outwit
562 the COVID-19 pandemic. It will be of utmost interest to monitor the polarity and specificity
563 elicited by current COVID-19 vaccines and to correlate these recognition profiles with failed
564 immunization, reinfection and emergence of severe disease.

565

566

567 SUPPLEMENTAL MATERIALS

568

569 Material and methods

570 **Patient and cohort characteristics.** All clinical studies were conducted after written informed
571 consent in accordance with Good Clinical Practice guidelines and the provisions of the
572 Declaration of Helsinki. Cohorts' characteristics are detailed in Table S1, Figure 1A and Figure
573 S1. Two cohorts of cancer patients (from the pre-COVID-19 era and from the COVID-19 era)
574 and three cohorts of healthy volunteers (from the pre- COVID-19 era and from the COVID-19
575 period including a cohort of vaccinees) were exploited to set up the translational research
576 analyses. Peripheral blood mononuclear cells (PBMC) were provided by Gustave Roussy

577 Cancer Campus (Villejuif, France) and IHU Méditerranée Infection (Marseille, France) (see
578 Blood analyses section).

579
580 **Contemporary clinical studies (COVID-19 era): 1/ ONCOVID clinical trial and regulatory**
581 **approvals.**

582 **Principles.** The protocol is available at <https://clinicaltrials.gov/ct2/show/NCT04341207>.
583 Gustave Roussy Cancer Center sponsored the trial named `ONCOVID` and collaborated with
584 the academic authors on the trial design and on the collection, analysis, and interpretation of
585 the data. Sanofi provided trial drugs. Protocol approval was obtained from an independent
586 ethics committee (ethics protocol number EudraCT No: 2020-001250-21). **Patients.**
587 ONCOVID eligible patients were all comorbid adults with advanced solid tumors or advanced
588 hematological malignancies spontaneously presenting at Gustave Roussy between April 10th,
589 2020 and January 15th, 2021 (data cut-off for our analyses). **Trial design.** Cancer patients were
590 screened for SARS-CoV-2 virus carriage by nasopharyngeal sampling at every hospital visit.
591 The presence of SARS-CoV-2 RNA was detected by RT-qPCR assay in a BSL-2 laboratory.
592 Asymptomatic and symptomatic patients (*i.e* presenting with fever ($t^{\circ}>38^{\circ}\text{C}$) and/or cough
593 and/or shortness of breath and/or headache and/or fatigue and/or runny nose and/or sore throat,
594 anosmia/ageusia) with a positive SARS-CoV-2 RT-qPCR test, shifted to the interventional
595 phase (tailored experimental approach with Hydroxychloroquine and Azithromycin therapy in
596 symptomatic SARS-CoV-2 positive subjects). Asymptomatic or symptomatic patients with
597 negative SARS-CoV-2 RT-qPCR tests continued their standard of care anti-cancer treatments.
598 Repeated RT-qPCR for SARS-CoV-2 on nasopharyngeal swabs and blood samples were
599 performed to monitor the status for SARS-CoV-2 and the immune response, respectively, in
600 COVID-19 positive and negative patients. The COVID-19 severity was defined based on
601 oxygen, imaging and hospitalization criteria (WHO criteria). Unexposed and exposed
602 individuals included in the ONCOVID trial during the first surge were followed-up by
603 telephone interview at 12-months in order to record documented COVID-19 infections and
604 degree of severity (WHO criteria) during the successive surges. **Samples for translational**
605 **research.** PMBCs were isolated less than 8 hours after the blood collection (at patient inclusion
606 and at every hospital visit) and kept frozen at -80°C . **2/ PROTECT-Cov clinical trial and**
607 **regulatory approvals. Principles.** IHU Méditerranée Infection sponsored the trial named
608 `PROTECT-Cov` and collaborated with the academic authors on the trial design and on the
609 collection, analysis, and interpretation of the data. Protocol approval was obtained from an
610 independent ethics committee (ethics protocol number ANSM No: 2020-A01546-33). The trial
611 was conducted in accordance with Good Clinical Practice guidelines and the provisions of the
612 Declaration of Helsinki. All patients provided written informed consent. **Subjects.** PROTECT-
613 Cov eligible subjects were members of the same family/home composed of two or more people
614 and selected from the microbiology laboratory register on SARS-Cov-2 tests performed
615 between March 23 and April 10, 2020. **Trial design.** Members of the same family/home who
616 had at least one (a)symptomatic COVID-19 + case (RT-qPCR <35 Ct values for SARS-CoV-2
617 on nasopharyngeal swabs) and at least one member with negative RT-qPCR for SARS-CoV-2
618 (≥ 35 Ct) were screened. A telephone interview was conducted in order to confirm and complete
619 the list of family circles in connection with the positive case. The compliant subjects finally
620 selected were invited to come back to the IHU Méditerranée Infections hospital where they

621 were included in the trial and had a blood test. **3/ COVID-SER clinical trial and regulatory**
622 **approvals. Principles.** At the "Hospices Civils de Lyon", France was conducted the trial named
623 COVID-SER. Protocol approval was obtained from an independent ethics committee (the
624 national review board for biomedical research, Comité de Protection des Personnes Sud
625 Méditerranée, ID-RCB-2020-A00932-37). The clinical study was registered on
626 ClinicalTrial.gov (NCT04341142). Written informed consent was obtained from all
627 participants and the study. **Subjects. COVID-SER** eligible subjects were health care workers
628 who received the Pfizer–BioNTech mRNA COVID-19 vaccine BNT162b2. All subjects with
629 a positive SARS-CoV-2 RT-PCR prior vaccination and/or a positive serological result with
630 Wantai Ab total kit at the pre-vaccination visit were considered as convalescent. Blood
631 sampling was performed before vaccination and 4 weeks after receiving 1 or 2 doses of vaccine
632 for naive and convalescent health care workers respectively. According to French procedures,
633 a written non-opposition to the use of donated blood for research purposes was obtained from
634 healthy volunteers. The donors' personal data were anonymized before transfer to our research
635 laboratory. We obtained approval from the local ethical committee and the French ministry of
636 research (DC-2008-64) for handling and conservation of these samples. Human biological
637 samples and associated data were obtained from NeuroBioTec (CRB HCL, Lyon France,
638 Biobank BB-0033-00046) and Virginie Pitiot.

639
640 **Clinical studies from the Pre-COVID-19 era: 1/ Series of patients with cancer:** This cohort
641 is composed of different IGR clinical trials. Patients were included and blood was collected and
642 banked between 1999 and 2018 (Pre-COVID-19 era). **Clinical studies: 1/** Patients with acute
643 myeloid leukemia admitted in the Hematology Department of IGR in Villejuif, France,
644 between March 2008 and March 2009 were included. The study was approved by the local
645 ethics committee (Comité de Protection des Personnes (CPP) Hopital Bicêtre –CALEX
646 protocol, n1 ID RCB 2007-A01074-49, date 29 February 2008). The main clinical and
647 biological characteristics of the patients are summarized in [30] PMBC were isolated less than
648 8 hours after the blood collection (before chemotherapy) and were kept frozen at -80°C. 2/
649 Phase II vaccine trial immunizing cancer patients (diagnosed with inoperable Non-small cell
650 lung cancer after induction with four cycles of platinum-based chemotherapy) with autologous
651 DC-derived exosomes and cyclophosphamide (CTX) (Study code « Dex2 »: NCT01159288,
652 date 19 December 2005) [28]. Eligible patients required at least stabilization of their disease
653 prior to being on maintenance immunotherapy with sc injections of IFN γ - dendritic cell
654 derived-exosomes loaded with MHC class I and class II-restricted cancer antigens. PBMCs
655 were collected at baseline after the 4th cycle of platinum-based chemotherapy, before
656 metronomic CTX followed by exosome injections and were kept frozen at -80°C. 3/ Phase I/II
657 study of intradermal and subcutaneous immunization with the recombinant MAGE-3 protein in
658 patients with MAGE-3 positive, measurable non visceral metastatic melanoma. The study was
659 approved by the local ethics committee (Study code « LUD 99 003 »: N-CSET : 99/090/752,
660 date 1 December 1999). Patients were required to have cutaneous melanoma with detectable
661 cutaneous and/or lymph node metastasis, but no visceral metastasis (AJCC 1997 stage III or
662 IVM1a). No chemotherapy, radiotherapy, or immunotherapy was allowed in the 4-week period
663 before the first vaccination. PBMCs were collected at baseline before the first vaccination and

664 were kept frozen at -80°C . 4/Adult patients with metastatic or locally advanced solid
665 malignancy, measurable or evaluable disease who were refractory to standard therapy were
666 eligible for the study (Phase I IMAIL-2 trial approved by the Kremlin Bicêtre Hospital Ethics
667 Committee [no 07–019] and the Agence Française de Sécurité Sanitaire des Produits de Santé
668 [no A70385–27; EudraCT N^o:2007–001699–35 in 2007] [79]. They received Imatinib mesylate
669 (IM) combined with increasing doses of IL-2. PMBCs were isolated less than 8 hours after the
670 blood collection (at baseline before treatment) and were kept frozen at -80°C . 2/ **Series of**
671 **patients without cancer** : Peripheral blood was obtained from healthy volunteers at the
672 *Etablissement Français du Sang* (EFS, Paris France, n 18EFS031 date 24 September 2018).

673 **Blood analyses.** Blood samples (for serum and PBL) were drawn from patients enrolled in the
674 different cohorts presented in the cohort description section above. Whole human peripheral
675 blood was collected into sterile vacutainer tubes. **Anti-SARS-CoV-2 immunoglobulins**
676 **measurements.** Serum was collected from whole blood after centrifugation at 600 g for 10 min
677 at room temperature and transferred to -80°C freezer to await analysis. Serological analysis
678 SARS-CoV-2 specific IgA, IgM and IgG antibodies were measured in 119 serum samples from
679 87 patients (Supplementary Material Figure 1) with The Maverick™ SARS-CoV-2 Multi-
680 Antigen Serology Panel (Genalyte Inc. USA) according to the manufacturer's instructions. The
681 Maverick™ SARS-CoV-2 Multi-Antigen Serology Panel (Genalyte Inc) is designed to detect
682 antibodies to five SARS-CoV-2 antigens: nucleocapsid, Spike S1 RBD, Spike S1S2, Spike S2
683 and Spike S1 or seasonal HCoV -NL-63 nucleocapsid, -OC-43, -229E and -HK-U1 Spike in a
684 multiplex format based on photonic ring resonance technology. This system detects and
685 measures with good reproducibility changes in resonance when antibodies bind to their
686 respective antigens in the chip. The instrument automates the assay. Briefly, 10 μl of each serum
687 samples were added in a sample well plate array containing required diluents and buffers. The
688 plate and chip are loaded in the instrument. First the chip is equilibrated with the diluent buffer
689 to get baseline resonance. Serum sample is then charged over the chip to bind specific
690 antibodies to antigens present on the chip. Next, chip is washed to remove low affinity binders.
691 Finally, specific antibodies of patients are detected with anti-IgG or -IgA or -IgM secondary
692 antibodies. **Isolation of peripheral blood mononuclear cells (PBMCs) from fresh blood**
693 **sampling.** Venous blood samples (10ml to 30ml) were collected in heparinized tubes (BD
694 Vacutainer® LH 170 U.I., Dutscher, UK). On the same day, blood was processed in a biosafety
695 level 2 laboratory at Gustave Roussy Institute, Villejuif, France, or in IHU Méditerranée
696 Infection, Marseille, France. Peripheral blood mononuclear cells (PBMCs) were freshly
697 isolated by LSM, Lymphocyte Separation Medium (Eurobio Scientific, France) density
698 gradient centrifugation according to manufacturer's instructions. (Leucosep tubes, Greiner;
699 Biocoll, Bio&SELL). PBMCs were then collected, washed once with phosphate-buffered saline
700 solution (PBS) and aliquoted in 1ml of cryopreservation medium (CryoStor®, STEMCELLS
701 Technologies, USA) in cryovials (two cryovials per patient). Cryovials (Cryotube™vials
702 ThermoFisher Scientific, Denmark) were conserved for 24h at -80°C in a cryo-freezing
703 container (Mr.Frosty™, Thermo Fisher Scientific) before storage in liquid nitrogen.

704 **Viral studies. Biosafety levels for in vitro experiments.** Frozen PBMCs from patients with a
705 confirmed negative RT-qPCR for SARS-CoV-2 genome at the time of blood drawing were
706 processed in a biosafety level 2 laboratory at Gustave Roussy Institute, Villejuif, France. All
707 samples from patients with positive RT-qPCR were processed in a biosafety level 3 laboratory

708 at Henri Mondor Hospital, Créteil, France. When a patient was sampled at different timepoints,
709 samples were processed together in the same laboratory. **RT-qPCR analysis.** SARS-CoV-2
710 diagnostic testing of clinical nasopharyngeal swabs or other samples by RT-qPCR was
711 conducted from 14 March to 23 March 2020 at an outside facility using the Charité protocol.
712 From the 23th March 2020 testing was performed internally at the Gustave Roussy. The cycle
713 thresholds were collected only for assays performed at Gustave Roussy. Nasopharyngeal swab
714 samples were collected using flocked swabs (Sigma Virocult) and placed in viral transport
715 media. SARS-CoV-2 RNA was detected using one of two available techniques at Gustave
716 Roussy: the GeneFinder COVID-19 Plus RealAmp kit (ELITech Group) targeting three regions
717 (*RdRp* gene, nucleocapsid and envelope genes) on the ELITE InGenius (ELITech Group) or the
718 multiplex real-time RT-PCR diagnostic kit (the Applied Biosystems TaqPath COVID-19 CE-
719 IVD RT-PCR Kit) targeting three regions (ORF1ab, nucleocapsid and spike genes) with the
720 following modifications. Nucleic acids were extracted from specimens using automated
721 Maxwell instruments following the manufacturer's instructions (Maxwell RSC simplyRNA
722 Blood Kit; AS1380; Promega). Real-time RT-PCR was performed on the QuantiStudio 5 Dx
723 Real-Time PCR System (Thermo Fisher Scientific) in a final reaction volume of 20 µl,
724 including 5 µl of extracted nucleic acids according to the manufacturer instruction. **Viral lysates
725 and their production.** SARS-CoV-2 IHUMI2, IHUMI845, IHUMI846, IHUMI847 (early 2020
726 episode), IHUMI2096 (20A.EU2, B.1.160) and IHUMI2514 (20C, B.1.367) [80] IHUMI3076
727 (20I/501Y.V1, B.1.1.7), IHUMI3147 (20H/501Y.V2, B.1.351) and IHUMI3191
728 (20J/501Y.V3, P.1) strains were isolated from human nasopharyngeal swab as previously
729 described [35] and grown in Vero E6 cells (ATCC CRL-1586) in Minimum Essential Medium
730 culture medium (MEM) with 4% fetal calf serum (FCS) and 1% L-glutamine. Influenza strains
731 H1N1 (0022641132) and H3N2 (8091056304) were isolated then produced from human
732 nasopharyngeal swab in MDCK cells (ATCC CCL-34) in MEM with 10% FCS and 1% L-
733 glutamine. All these clinical isolates were characterized by whole viral genome sequencing
734 from culture supernatants. Coronavirus OC43 (ATCC vr-1558) was grown in HCT8 cells
735 (ATCC CCL-244) in RPMI with 10% FCS. Coronavirus 229E (ATCC vr-740) was grown in
736 MRC5 cells (ATCC CCL-171) in MEM with 10% FCS. All reagents for culture were from
737 ThermoFisher Scientific and all cultures were incubated at 37°C under 5% CO₂ without
738 antibiotics. All viral strains were produced in 125 cm² cell culture flasks. When destruction of
739 cell monolayer reached approximately 80%, between 2 to 7 days according to cell line and viral
740 strain, culture supernatant was harvested. After low speed centrifugation to remove cells and
741 debris (700 x g for 10 min.) supernatants were filtered through 0.45 then 0.22 µm pore-sized
742 filters. These viral suspensions were then inactivated for 1 hour at 65°C before use. Batches of
743 scrapped control uninfected cells were rinsed twice in PBS, and then finally resuspended in 5
744 ml of PBS at 5.10⁵ cells/ml. All cells and antigens were tested negative for Mycoplasma before
745 use.

746 **In vitro stimulation assays.** *Cross-presentation assay or peripheral blood lymphocyte
747 stimulation with autologous monocyte derived- dendritic cells (DC).* Frozen PBMCs were
748 thawed, washed and resuspended in RPMI 1640 media (GIBCO). Viability and count were
749 evaluated using a Vi-Cell XR Cell Counter (Beckman Coulter, Brea). PBMC were then cultured
750 in RPMI 1640 supplemented with 10% human AB serum, 1mM Glutamine, 1% sodium
751 pyruvate, 1% HEPES, 1% penicillin/streptomycin at a cell density of 0.5M cells/cm² for 2 hours
752 at 37°C, 5% CO₂ and separated into adherent and non-adherent cell populations. Non-adherent
753 cells, containing Peripheral Blood Lymphocytes (PBL), were collected and cultured 4 days at
754 37°C, 5% CO₂ in IMDM medium (Sigma-Aldrich, UK), supplemented with 10% human AB
755 serum (Institut de Biotechnologies Jacques Boy, France), 1mM Glutamine

756 (GIBCO/ThermoFisher Scientific, UK) 1% Sodium Pyruvate (GIBCO/ThermoFisher
757 Scientific, UK), 1% HEPES (GIBCO/ThermoFisher Scientific, UK), 1%
758 penicillin/streptomycin (GIBCO/ThermoFisher Scientific, UK) and 200 UI/mL rhIL-2
759 (Miltenyi, Germany). The adherent cell population was cultured for 3 days, at 37°C, 5% CO₂,
760 in a mo-DC differentiating media containing RPMI 1640 supplemented with 10% human AB
761 serum, 1mM Glutamine, 1% sodium pyruvate, 1% HEPES, 1% penicillin /streptomycin,
762 1000UI/mL rhGM-CSF (Miltenyi) and 250UI/mL human IFN α -2b (Introna, MSD France). At
763 day 3, adherent cells were slowly detached by pipetting after 20 minutes of incubation at 4°C
764 and 20.000 cells were seeded in 96 well round bottom plate and were pulsed, or not (control
765 condition), overnight, at 37°C, 5% CO₂, with 1/10 heat inactivated viral lysates, or their
766 respective control (see viral lysates production section). Spinoculation (800g for 2h, Centrifuge
767 5810R, Eppendorf, Germany) was next performed to ensure synchronized capture of the viral
768 particles by mo-DCs. For activation and maturation, adherent cells were stimulated with LPS
769 (10 ng/mL, Thermofisher) and GM-CSF (1000UI/mL). After 6h, mo-DCs were washed twice
770 to remove LPS from the media and 100 000 PBL/well were seeded onto mature mo-DCs. PBL
771 alone served as negative control, and PBL stimulated with anti-CD3 and anti-CD28 microbeads
772 (1 μ L/mL, Dynabeads T-Activator, InVitrogen) as a positive control. moDC-PBL co-culture
773 was incubated at 37°C, 5% CO₂ for 48h and supernatants were harvested and stored at -20°C.

774 ***Multiplex Cytokine Analysis or bead-based multiplex assays.*** moDC-PBL co-culture
775 supernatants were analyzed using bead-based multiplex kit assays (MACSplex cytokine 12
776 human, Miltenyi) according to the manufacturer protocol. Briefly, 50uL of supernatant were
777 used with a MACSPLEX Cytokine12 Capture Beads (Miltenyi, France) to measure the
778 concentration of 12 cytokines (GM-CSF, IFN- α , IFN- γ , IL-10, IL-12, IL-17A, IL-2, IL-4, IL-
779 5, IL-6, IL-9, TNF-a). Bead fluorescence was acquired on a CytoFLEX flow cytometer
780 (Beckman Coulter) for samples processed at Gustave Roussy Institute and on a FACSARIA
781 Fusion (Becton Dickinson) for samples processed in the biosafety level 3 laboratory at Henri
782 Mondor Hospital. FlowJo (Treestar, Ashland, OR, USA) software was used for analysis.

783 ***Peptide-based assay.*** Lyophilized peptides were dissolved in sterile water and used at 2 μ g/mL
784 in RPMI 1640 glutamax media (GIBCO) supplemented with 1% penicillin/streptomycin
785 (GIBCO). 185 single peptides were plated in duplicates in 96 well round bottom TPP treated
786 culture plates. Peptide plates were then stored at -80°C until use. The day of the experiment,
787 peptide plates were thawed at room temperature. Frozen PBMCs were thawed, washed and
788 resuspended in RPMI 1640 media (GIBCO). Viability and count were evaluated using a Vi-
789 Cell XR Cell Counter (Beckman Coulter, Brea). PBMCs were then plated in RPMI 1640
790 glutamax media (GIBCO) supplemented with 1% penicillin/streptomycin (GIBCO), with
791 200UI/mL rhIL-2 (Miltenyi) and 200UI/mL rhIL-15 (Miltenyi) at a cell density of 10x10³ cells
792 and incubated with each peptide at 37°C, 5% CO₂. PBMCs were stimulated with 60 ng/mL
793 OKT-3 antibody (ThermoFisher Scientific, clone OKT3) or with 10 μ g/mL phytohemagglutinin
794 as positive controls and PBMCs alone served as negative controls. After 6 hours, 20 μ L of
795 human AB serum was added to each well and plates were incubated at 37°C, 5% CO₂ for 6
796 additional days. On day 7, supernatants were harvested and frozen at -80°C. Concentration of

797 IFN γ , IL-9, IL-5 and IL-17A in the culture supernatant was determined using a commercial
798 ELISA kit (ELISA Max Deluxe set human IFN- γ , Biolegend).

799 ***Positivity threshold determination for cytokine concentration using multiplex assays and***
800 ***commercial ELISA assays.*** For multiplex assays (or ELISA), a 4 parameter logistic regression
801 was fitted for each cytokine based on the APC mean fluorescent intensity(or Optical Density)
802 of standard dilution samples using nlpr(v0.1-7). This model was then used to calculate the
803 concentration of each sample of unknown concentration. For multiplex assays, a ratio was
804 computed for each cytokine using the cytokine concentration measured in response to each
805 virus (SARS-CoV-2, HCoV-229E, HCoV-OC43) divided by the median concentration of their
806 respective biological controls (Vero 81, MRC5, HCT8). A positivity threshold was set up based
807 on the ratio for each cytokine. A ratio of above 1.5 minimum was requested to consider the
808 supernatant “positive” for a cytokine. When necessary, a higher threshold was set up as such,
809 median cytokine concentration of the biological controls + 2 times the standard deviation of
810 the biological control concentrations divided by the median concentration. For ELISA assays,
811 a ratio was computed as the concentration of the sample divided by the mean concentration of
812 the negative controls.

813 ***COVID IGRA Biomérieux assay utilized for the COVID-SER clinical trial vaccinees [42].***
814 Fresh blood collected in heparanized tubes was stimulated for 22 hours at 37°C under 5% of
815 CO₂ with peptide pools targeting RBD (46 peptides) (bioMérieux,France) diluted in IFA
816 solution (bioMérieux, France). The IFA solution was used as a negative control and a mitogen
817 was used as a positive control. The peptides (15-mer) encompassed the whole RBD protein
818 sequence and overlapped by 5-residues. The concentration of IFN γ in the supernatant was
819 measured using the VIDAS automated platform (VIDAS® IFN γ RUO, bioMérieux). The
820 positivity range was 0.08 -8 IU/mL and IFA positivity thresholds were defined at 0.08 IU/mL.
821 The IFN γ response was defined as positive when the IFN γ concentration of the test was above
822 threshold and the negative control was below threshold or when the IFN γ concentration of the
823 test minus IFN γ concentration of the negative control was above threshold. All positive controls
824 were \geq 8 IU/mL.
825

826 **Reagents: culture media, cytokines, ELISA and multiplex assays. PBMC isolation.** Blood
827 samples were collected in heparinized tubes BD Vacutainer® LH 170 U.I., from Dutscher
828 (catalog reference: 367526), diluted in PBS 1X purchased from Eurobio Scientific (catalog
829 reference: CS3PBS01-01) and transferred in Leucosep™ - 50mL purchased from Greiner Bio-
830 One (catalog reference: 227290). Blood was centrifuged using MF48-R Centrifuge from
831 AWEL Industries (catalog reference: 20023001). PBMC were collected in Centrifuge tube
832 50mL TPP from Dutscher (catalog reference: 91050), washed with PBS 1X, resuspended in
833 CryoStor® CS10 purchased from STEMCELL™ technologies (catalog reference: 5100-0001)
834 and transferred in Cryotube™ vials from ThermoFisher Scientific (catalog reference: 377267).
835 Samples were finally conserved for 24h at -80°C in a cryo-freezing container Mr.Frosty™ from
836 Thermo Fisher Scientific before storage in liquid nitrogen. ***Cross-presentation assay or***
837 ***peripheral blood lymphocyte stimulation with autologous monocyte derived- dendritic cells***
838 ***(DC).*** Frozen PBMCs were thawed, washed and resuspended in RPMI Medium 1640 (1X)
839 purchased from GIBCO (catalog reference: 31870-025). Counting and viability were evaluated

840 using Vi-CELL™ XR Cell Viability Analyzer from Beckman Coulter (catalog reference:
841 AV13289). To separate adherent and non-adherent cell populations, PBMC were transferred in
842 6 or 24 well flat bottom Sterile tissue culture testplate TPP purchased from Dutscher (catalog
843 reference: 92006 / 92024) and cultured in complex medium (Complex Medium 1) containing
844 human AB serum (catalog reference: 201021334), purchased from Institut de Biotechnologies
845 Jacques Boy France), RPMI Medium 1640 (1X) (catalog reference: 31870-025), Sodium
846 Pyruvate (catalog reference: 11360-039), Penicillin /Streptomycin (catalog reference: 15140-
847 122), L-Glutamine (200mM) (catalog reference: 25030-024) HEPES Buffer Solution (catalog
848 reference: 15630-056), MEM NEAA (catalog reference: 1140-035), purchased from
849 GIBCO/ThermoFisher Scientific. The Non-adherent fraction was cultured in another complex
850 medium (Complex Medium 2) containing human AB serum, Iscove's Modified Dulbecco's
851 Medium (catalog reference: 13390), from Sigma-Aldrich, Sodium Pyruvate (catalog reference:
852 11360-039), Penicillin/Streptomycin (catalog reference: 15140-122), L-Glutamine (200mM)
853 (catalog reference: 25030-024) HEPES Buffer Solution (catalog reference: 15630-056), MEM
854 NEAA (catalog reference: 1140-035) from GIBCO/ThermoFisher Scientific and Recombinant
855 Human IL-2 (PHAR000306) from Gustave Roussy Institute pharmacy. The adherent fraction
856 was differentiated into monocyte derived- dendritic cells (mo-DC) in a mo-DC differentiating
857 media constituted with Complex Medium 1 supplemented with Recombinant Human GM-CSF
858 Premium purchased from Miltenyi (catalog reference: 130-093-867) and human IFN α -2b
859 (Introna) purchased from MSD (France) (catalog reference: PHAR008943). For activation and
860 maturation, DCs were stimulated with LPS purchased from Invivogen (catalog reference:) and
861 GM-CSF purchased from Miltenyi Biotec (catalog reference: 130-093-867). PBL and mo-DC
862 were finally co-cultured into 96 well V bottom Sterile Nunc™ plate, VWR purchased from
863 Dutscher (catalog reference: 92097). For positive control, PBL were stimulated with
864 Dynabeads™ Human T-Activator CD3/CD28 purchased from GIBCO / ThermoFisher
865 Scientific (catalog reference: 11131D). All cell cultures were performed at 37°C, 5% CO₂ into
866 Heraeus® incubator purchased from Kendro Laboratory Products, ThermoFisher Scientific
867 (catalog reference: BB 6220) And supernatants were transferred into 96 well V bottom Sterile
868 Nunc™ plate, VWR purchased from Dutscher (catalog reference: 734-0491) and frozen.
869 **Peptide-based assay.** 96 well V bottom Sterile Nunc™ plate were coated with peptides at
870 2 μ g/mL in RPMI Medium 1640 (1X) (catalog reference: 31870-025) supplemented with 1%
871 Penicillin/Streptomycin (catalog reference: 15140-122) and conserved at -80°C. PBMCs were
872 then thawed and plated in plate containing peptides in RPMI Medium 1640 (1X) (catalog
873 reference: 31870-025) supplemented with 1% Penicillin/Streptomycin (catalog reference:
874 15140-122) supplemented with Recombinant Human IL-15 Premium grade from Miltenyi
875 biotec (catalog reference: 130-095-765) and Recombinant Human IL-2 (PHAR000306) from
876 Gustave Roussy Hospital. For positive, PBMC were stimulated with functional grade CD3,
877 OKT3 purchased from ThermoFisher Scientific (catalog reference: 16-0037-85). Cell cultures
878 were then supplemented with human AB serum (catalog reference: 201021334) purchased from
879 Institut de Biotechnologies Jacques Boy (France) and cultured at 37°C, 5% CO₂. **Cytokines**
880 **monitoring.** Supernatants from cultured cells from Cross-presentation assay were monitored
881 using the MACSplex Cytokine 12 Kit human purchased from Miltenyi Biotec (catalog
882 reference: 130-099-169). Acquisitions and analyses were performed on CytoFLEX S purchased
883 from Beckman Coulter (catalog reference: B75442)/FACSaria Fusion purchased from

884 BD Biosciences and FlowJo Software from Treestar respectively. Whereas Supernatants from
885 cultured cells from peptide-based assay were monitored using ELISA tests purchased from
886 BioLegend: ELISA MAXTM Deluxe Set Human IFN- γ (catalog reference: 430104) ELISA
887 MAXTM Deluxe Set Human IL-17 (catalog reference: 433914) and ELISA MAXTM Deluxe Set
888 Human IL-9 (catalog reference: 434705).

889
890 **Rationale of peptide selection and peptide synthesis (Refers to Table S6).** Peptide selection
891 and synthesis: the peptides from the spike and nucleocapsid proteins were selected by dividing
892 the sequences of the SARS-CoV-2 spike protein (RefSeq ID QHD43416.1) and of the
893 nucleocapsin protein (RefSeq ID QHD43423.2) in non-overlapping 15 amino acid segments.
894 The peptides from the membrane protein were selected by dividing the sequence of 2 potential
895 immunogenic regions of the SARS-CoV-2 (RefSeq QHD43422.1) membrane protein in
896 overlapping 15 amino acid segments. The peptides from the ORF8 and ORF10 proteins were
897 selected by dividing the sequences of the SARS-CoV-2 ORF8 protein (RefSeq ID
898 QHD43422.1) and of the ORF10 protein (RefSeq ID QHI42199.1) in overlapping 15 amino
899 acid segments. The peptides from ORF3 and some for ORF8 were selected based on a previous
900 study [81]. The SARS-CoV-1 peptides were peptides found to be immunogenic in previous
901 reported studies. The peptides were synthesized by peptides&elephants GmbH (Berlin,
902 Germany). The peptide pools for the controls for Influenza, EBV and CMV were acquired from
903 peptides&elephants GmbH (Berlin, Germany) order numbers LB01774, LB01361 and
904 LB01232 respectively.

905
906
907 **Statistical analysis.** All calculations, statistical tests, and data visualization were performed
908 using R v4.0.3. All analyses were performed on independent samples, excepting when the
909 presence of replicates is mentioned. The associations between continuous variables were
910 evaluated using Spearman correlation. Group comparisons were performed using non-
911 parametric test with the wilcox.test R function: the Wilcoxon-Mann-Whitney test for
912 independent samples, and the Wilcoxon signed rank test for paired samples. The comparison
913 of categorical data was performed using the Fisher exact test with the fisher.test R function.
914 Hierarchical clustering was performed with the package hclust, using the euclidean distance.
915 Linear and logistic regressions were performed with respectively the lm and the glm R base
916 functions. A peptide set enrichment analysis was performed with the R package fgsea (version
917 1.14.0), using as statistic the t-value of the coefficient of univariable linear regressions of the
918 logarithm-normalized IL-2 secretion on the different peptides. All hypothesis tests (including
919 those of regression coefficients) were two-sided and considered as statistically significant when
920 $p < 0.05$. Graphical illustrations were drawn using the standard R packages dedicated to the data
921 visualization (ggplot2, ggpubr, corrplot, complexheatmap, circlize, and Hmisc).

922

923 Acknowledgments: We thank the ET-EXTRA team (Biological Resource Center (NF 96-600) and the
924 microbiology team for technical help. We thank the staff from health and safety of Gustave Roussy Cancer Campus
925 for helping to set up the translational research studies. We are thankful to the Genalyte for their supportive help.
926 We are thankful to Jeanne Magnan and Alexandre Trubert for their supportive help. Lyon COVID Study GROUP
927 and authors thank the Hospices Civils de Lyon and by Fondation des Hospices Civils de Lyon and all the personnel
928 of the occupational health and medicine department of Hospices Civils de Lyon who contributed to the samples
929 collection.

930 **Contributions:** L.D., L.Z., A.M. and F.B. conceived and designed the clinical trial. L.Z. conceived and designed
931 the translational research, interpreted the data and formulated figure design. A.G., F-X.D., S.T., C.M., L.A., B.B.,
932 A.St., B.G., M.Mer., F.S., A.M., L.D. included patients in the clinical trial. J-E.F, I.L., A.C., M.Maz., C.T., Y.H.,
933 M.Pi., M.G., B.K., G.F., A.D., C.F., A.T. and J.M. carried out all the experiments. J-E.F., and D.D. performed all
934 the statistical analyses. L.D., A.G. C.A-C-S. and G.M collected the clinical data. Sophie Assan provided the
935 information from the HCL series with the contribution of BioMérieux. C.M , B.L.S., S.G. and S.C. analyzed and
936 provided the clinical data from the IHU. E.C. and F.G. performed the RT-qPCR. A-G.G., C. A-C-S., M.Maz. and
937 LD collected the biological data (ALC and Ct values). C.P. collected the samples. M.Maz., Y.H., E.P., C.F., G.F.,
938 C.T., A-G.G., B.K., A.T., and P.L. prepared the biological samples and provided some help for the experiments.
939 B.L.S performed the viral cultures and provided viral lysates. A-A.B. helped with experiments performed in a
940 BSL-3 confined environment. M.Mi. and G.G. performed the dosages of antibodies. E.d.S, MM and J.R.L
941 designed the epitopes and prepared the peptides. All the authors advised for the interpretation of the data. L.Z.
942 wrote the manuscript, with all authors contributing to writing and providing feedback.

943

944 **Funding:** L.D. has received support by the Philanthropia Fondation Gustave Roussy. The Gustave Roussy
945 sponsored clinical study on COVID-19 (ONCOVID; NCT NCT04341207 has been supported by the Fondation
946 Gustave Roussy, the Dassault family, Malakoff Humanis, Agnès b., Izipizi, and Ralph Lauren. A-G.G. and I.L.
947 were supported by Fondation pour la Recherche Médicale (FRM). Lyon COVID study GROUP are Biomerieux
948 employees or received grant from Biomérieux to perform experiments. L.Z. and G.K. were supported by RHU
949 Torino Lumière (ANR-16-RHUS-0008), ONCOBIOME H2020 network, the SEERAVE Foundation, the Ligue
950 contre le Cancer (équipe labellisée); Agence Nationale de la Recherche – Projets blancs; ANR under the frame of
951 E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC);
952 Cancéropôle Ile-de-France; FRM; a donation by Elior; the European Research Council (ERC); Fondation
953 Carrefour; High-end Foreign Expert Program in China (GDW20171100085 and GDW20181100051), Institut
954 National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx
955 Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination
956 (SOCRATE); CARE network (directed by Prof. Mariette, Kremlin Bicêtre AP-HP), and the SIRIC Cancer
957 Research and Personalized Medicine (CARPEM).

958

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

959 G.I. and M.P. were supported by Italian Ministry of Health (grants Ricerca CorrenteLinea 1, 1 ‘Infezioni
960 Emergenti e Riemergenti’, projects COVID-2020-12371675 and COVID-2020-12371817). M.Mi and G.G. were
961 supported by ANR Flash COVID-19 program and ARS-CoV-2 Program of the Faculty of Medicine from Sorbonne
962 University ICOViD programs (PI: G.G.). M.Mer. is a member of the Gates Foundation's innate immunity advisory
963 group and his work is supported by the Champalimaud Foundation through funds from grants UIDB/04443/2020,
964 LISBOA-01-0145-FEDER-022231 and LISBOA-01-0246-FEDER-000007. Over the last 5 years: AM has been a
965 Principal Investigator of Clinical Trials from the following companies: Roche/Genentech, BMS, Merck (MSD),
966 Pfizer, Lytix pharma, Eisai, Astra Zeneca/Medimmune, Tesaro, Chugai, OSE immunotherapeutics, SOTIO,
967 Molecular Partners, IMCheck, Pierre Fabre, Adlai Nortye. A.M. has been a Member of Clinical Trial Steering
968 Committees for NCT02528357 (GSK), NCT03334617 (AZ) and a Member of Data Safety and Monitoring Board:
969 NCT02423863 (Sponsor: Oncovir), NCT03818685 (Sponsor: Centre Léon Bérard). A.M. has been a compensated
970 member of the following Scientific Advisory Boards : Merck Serono, eTheRNA, Lytix pharma, Kyowa Kirin
971 Pharma, Novartis, BMS, Symphogen, Genmab, Amgen, Biothera, Nektar, Tesaro/GSK, Oncosec, Pfizer, Seattle
972 Genetics, Astra Zeneca/Medimmune, Servier, Gritstone, Molecular Partners, Bayer, Partner Therapeutics, Sanofi,
973 Pierre Fabre, RedX pharma, OSE Immunotherapeutics, Medixi, HiFiBio, IMCheck, MSD, iTeos, Innate Pharma,
974 Shattuck Labs, MedinCell, Tessa Therapeutics, Deka Biosciences. A.M. has provided compensated
975 Teaching/Speaker activities for Roche/Genentech, BMS, Merck (MSD), Merck Serono, Astra
976 Zeneca/Medimmune, Amgen, Sanofi, Servier. AM has provided compensated Scientific & Medical Consulting
977 for Roche, Pierre Fabre, Onxeo, EISAI, Bayer, Gentecel, Rigontec, Daichi Sankyo, Imaxio, Sanofi/BioNTech,
978 Molecular Partners, Pillar Partners, BPI, Faron, Applied Materials. AM has benefited of Non-Financial Support
979 (travel expenses) from Astra Zeneca, BMS, Merck (MSD), Roche. A.M. is a shareholder of Pegascy SAS, Centessa
980 Pharmaceuticals, HiFiBio, Shattuck Labs. A.M. has received pre-clinical and clinical research grants (Institutional
981 Funding) from Merus, BMS, Boehringer Ingelheim, Transgene, Fondation MSD Avenir, Sanofi and Astra Zeneca.
982 BLS has received founding from the French Government under the “Investments for the Future” programme
983 managed by the National Agency for Research (ANR), Méditerranée-Infection 10-IAHU. E.D. reports grants and
984 personal fees from ROCHE GENENTECH, grants from SERVIER, grants from ASTRAZENECA, grants and
985 personal fees from MERCK SERONO, grants from BMS, grants from MSD, grant and personal fees from
986 Boehringer and was supported by INCa 2018-1-PL BIO-06-1 outside the submitted work. J-P.S was supported by
987 MSD Avenir and has received and personal fees from Roche, MSD, BMS, Lilly, AstraZeneca, Daiichi-Sankyo,
988 Mylan, Novartis, Pfizer, PFO, LeoPharma and Gilead outside the submitted work.

989 **The authors declare the following competing interests:** L.Z. and G.K. are cofounders of everImmune, a biotech
990 company devoted to the use of commensal microbes for the treatment of cancers. A.G., A.B.T. and A.M. as part
991 of the Drug Development Department (DITEP) are Principal/sub-Investigator of Clinical Trials for Abbvie,
992 Adaptimmune, Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex
993 Pharmaceuticals, Astra Zeneca, Astra Zeneca Ab, Aveo, Bayer Healthcare Ag, Bbb Technologies Bv, Beigene,
994 Bioalliance Pharma, Biontech Ag, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol
995 Myers Squibb, Bristol-Myers Squibb International Corporation, Ca, Celgene Corporation, Cephalon, Chugai
996 Pharmaceutical Co., Clovis Oncology, Cullinan-Apollo, Daiichi Sankyo, Debiopharm S.A., Eisai, Eisai Limited,
997 Eli Lilly, Exelixis, Forma Therapeutics, Gamamabs, Genentech, Gilead Sciences, Glaxosmithkline, Glenmark
998 Pharmaceuticals, H3 Biomedicine, Hoffmann La Roche Ag, Incyte Corporation, Innate Pharma, Institut De

999 Recherche Pierre Fabre, Iris Servier, Janssen Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin
1000 Pharm. Dev., Lilly France, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck KgaA,
1001 Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Molecular
1002 Partners Ag, Nanobiotix, Nektar Therapeutics, Nerviano Medical Sciences, Novartis Pharma, Octimet Oncology
1003 Nv, Oncoethix, Oncomed, Oncopeptides, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Ose Pharma,
1004 Pfizer, Pharma Mar, Philogen S.P.A., Pierre Fabre Medicament, Plexxikon, Rigontec GmbH, Roche, Sanofi
1005 Aventis, Sierra Oncology, Sotio A.S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, Tioma Therapeutics, Wyeth
1006 Pharmaceuticals France, Xencor, Y's Therapeutics, Research Grants from Astrazeneca, BMS, Boehringer
1007 Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi. Non-financial support (drug supplied) from
1008 Astrazeneca, Bayer, BMS, Boringher Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH TherAGuiX,
1009 Pfizer, Roche. N.L. reports to be a Speaker at Jazz Pharmaceutical. Lyon COVID study GROUP are Biomerieux
1010 employees or received grant from Biomérieux to perform experiments. F.S. reports consulting fees from Pfizer,
1011 BMS, MSD, Roche, Pierre Fabre Oncology, Leo Pharma, Bayer, Mylan/Viatris, Mundi Pharma, Vifor Pharma,
1012 Biogaran, Helsinn. D.D. reports consulting fees from Chugai and Roche. E.D. reports grants and personal fees
1013 from ROCHE GENENTECH, grants from SERVIER, grants from ASTRAZENECA, grants and personal fees
1014 from MERCK SERONO, grants from BMS, grants from MSD, grant and personal fees from Boehringer outside
1015 the submitted work. F.B. reports personal fees from Astra-Zeneca, Bayer, Bristol-Myers Squibb, Boehringer-
1016 Ingelheim, Eli Lilly Oncology, Hoffmann-La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer and
1017 Takeda, outside the submitted work. J-C.S. was a full-time employee of AstraZeneca between September 2017
1018 and December 2019. J-C.S. reports consultancy: Relay Therapeutics, Gritstone Oncology and shares: Gritstone,
1019 AstraZeneca, Daiichi-Sankyo, outside the submitted work. G.G. is a member of the scientific board of Luxia
1020 Scientific and reports consultancy for Pileje and Luxia Scientific, outside the submitted work.

1021 **Figure Legends**

1022

1023 **Figure 1. SARS-CoV-2 TH1/TC1 responses in COVID-19 and unexposed individuals.**

1024 **A.** Graphical representation of the prospective patient cohorts used for the study (refer to Table
1025 S1 and Table S2). **B.** First experimental in vitro stimulation assay of peripheral blood
1026 lymphocytes (PBL) using cross-presentation of viral lysates by autologous dendritic cells (DC).
1027 Twelve plex flow cytometric assay to monitor cytokine release in replicates. **C.** Mean fold
1028 changes (Log₂, F.C) between SARS-CoV-2-specific cytokine secretions of acute COVID-19
1029 patients or convalescent COVID-19 individuals and controls (also refer to S1C). **D.** Ratios of
1030 cytokine secretion between PBL stimulated with DC pulsed with SARS-CoV-2 (or the other
1031 CCC lysates) *versus* VeroE6 (or *versus* CCC respective control cell lines), at the acute or
1032 convalescent phases of COVID-19. One typical example is outlined in Figure S1A. Each dot
1033 represents the mean of replicate wells for one patient (Controls, n=304; Convalescent COVID-
1034 19, n=54; Acute COVID-19, n=24). Asterisks indicate statistically significant differences in
1035 comparison to the control group determined using two-sided Wilcoxon-Mann-Whitney test

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

1036 (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$). **E.** Spearman correlations between SARS-
1037 CoV-2-specific IL-2 (left panel) or IL-5 (right panel) release and anti-NC IgG antibody titers
1038 (Controls, $n=63$; Convalescent, $n=16$).

1039

1040 **Figure 2. Unexposed individuals susceptible to COVID-19 exhibited a SARS-CoV-2**
1041 **specific TH2 profile during the first surge of the pandemic.**

1042 **A-B.** Upper scheme: Outline of the prospective collection of blood samples used to identify
1043 COVID-19 resistant (yellow) *versus* susceptible (red) cancer patients (A, upper panel, Table
1044 S1, Table S4) and pie chart indicating the absolute numbers (and %) of patients reported as
1045 contact (resistant) or infected (susceptible) or unexposed (green) during one-year follow-up
1046 (B). Lower scheme: Outline of the prospective collection of blood samples used for the
1047 comparison of T cell responses in the cohort of cancer-free individuals who lived in the same
1048 household with family members tested positive for COVID-19 during the 2020 lock down
1049 (Table S3). **C.** Number of positive cytokines released by SARS-CoV-2-specific PBL during the
1050 cross-presentation assay (Figure 1B) in each group (Unexposed, $n=159$; Resistant, $n=48$;
1051 Susceptible, $n=22$). **D-E.** SARS-CoV-2-specific IL-2 (left panel) and IL-5 (right panel)
1052 secretion contrasting resistant (yellow) *versus* infected (red) cases. Each dot represents the ratio
1053 (D) of the replicate wells in one individual and the box plots indicate medians, 25th and 75th
1054 percentiles for each patient subset. The bar plots (E) represent the percentage of positive
1055 patients (resist., $n=41$; suscept., $n=19$). Fisher exact test to compare the number of cytokine
1056 positive patients across groups (* $p < 0.05$). **F.** SARS-CoV-2-specific IL-2/IL-5 ratios
1057 (means \pm SEM) in the different subsets presented in panel A. Refer to Figure S4 for the waterfall
1058 plots to visualize variations in the percentages of individuals with IL-2/IL-5 ratios $>$ or $<$ 1
1059 according to subject category. **G.** CCC (OC43 and 229E)-specific IL-2 ratio (left panel) or IL-
1060 5 secretion ratio (right panel) contrasting contact (resistant, yellow dots, $n=34$) *versus* infected
1061 (susceptible, red dots, $n=11$) cases. **H.** Spearman correlations between OC43 *and* SARS-CoV-
1062 2-specific IL-2 (left panel) and IL-5 (right panel) secretions in 156 controls. **I.** Anti-spike IgG
1063 titers (means \pm SEM) specific of seasonal betacoronaviruses in contact (resist., yellow dots,
1064 $n=34$) *versus* infected (suscept., red dots, $n=11$) cases. **J.** Scheme detailing the two groups of
1065 cancer-free individuals from the same hospital with opposite clinical phenotypes (multi-
1066 exposed individuals ($n=12$) versus patients re-infected with SARS-CoV-2 ($n=17$) patients) (J,
1067 left panel). Results of the cross-presentation assay against SARS-CoV-2 for IL-10 (J, right
1068 panel) and IL-2 (refer to Figure S5B). IL-5 levels at baseline and after TCR cross-linking are
1069 depicted in the middle panel. Each dot represents the mean of two replicates for one patient.

1070 All group comparisons were performed using two-sided Wilcoxon-Mann-Whitney test and
1071 asterisks indicate statistically significant differences ($*p<0.05$, $**p<0.01$, $***p<0.001$,
1072 $****p<0.0001$).

1073

1074 **Figure 3. Peptide recognition patterns in all distinct subsets of individuals: repertoire**
1075 **breadth of peptide does not predict resistance to COVID-19.**

1076 **A.** Experimental setting for the 186 peptide-based *in vitro* stimulation assays. **B.** Bicolor map
1077 of peptide recognition (positive in salmon, negative in purple, not determined in grey). Patients
1078 (n=164) were ordered in columns by unsupervised hierarchical clustering and peptides were
1079 ordered on rows according to recognition frequency. The left column details clinical
1080 information and the upper line indicates the peptide frequency and the names of the proteins.
1081 **C-D.** Percentages of positive peptides in individuals from the pre-COVID19 era (n=23) *versus*
1082 contemporary controls (n=100) (C, right panel) and in cancer (n=112) *versus* cancer free
1083 contemporary individuals (n=13) (C, left panel) and in uninfected (control, n=123) *versus*
1084 convalescent (recovery, n=25) (D, left panel) and resistant individuals (non-infected contact
1085 cases (n=45) *versus* susceptible (infected, n=18) individuals (D, right panel). Group
1086 comparisons were performed using two-sided Wilcoxon-Mann-Whitney test and asterisks
1087 indicate statistically significant differences ($*p<0.05$, $**p<0.01$, $***p<0.001$, $****p<0.0001$).

1088

1089 **Figure 4. Receptor Binding Domain (RBD)-directed TH1/TC1 recall responses predict**
1090 **resistance to COVID-19.**

1091 **A.** Linear regression analysis of the relative contribution (t-value corresponding to the
1092 regression coefficient) of each peptide to SARS-CoV-2-specific TH1/TC1 responses (measured
1093 as IL-2 secretion in responses to whole virus lysate in Fig. 1), as determined in the peptide-
1094 specific IFN γ secretion assay in 123 COVID-19 negative individuals. Statistically significant
1095 peptides ($p<0.05$) are annotated with asterisks (A, left panel). Peptides colored in blue
1096 reportedly harbor at least one mutation within SARS-CoV-2 variants (Table S7). Peptide set
1097 enrichment analysis plot (A, right panel). The contribution of each peptide to the SARS-CoV-
1098 2-specific IL-2 secretion was used to rank 164 peptides. The enrichment score of S1-RBD
1099 peptides suggested that this peptide set presented lower t-values than randomly expected
1100 ($p=0.048$) (A, right panel). **B-C.** Percentages of patients recognizing at least one S1-RBD
1101 peptide in the IFN γ ELISA of the peptide IVS assay across patients' groups described in Figure
1102 2A (B) or convalescent versus re-infected patients (C). **D.** Percentages of patients recognizing
1103 at least one S1-RBD peptide in the IFN γ ELISA of the peptide IVS assay in cancer and cancer

1104 free patients from the pre-COVID19 era. **E.** Percentages and absolute numbers of mutations
1105 contained in our S1-RBD peptide list reported in the current SARS-CoV-2 variants (refer to
1106 Table S7). The difference of the probability of mutation in S1-RBD region and in other regions
1107 was evaluated using logistic regression (Odd Ratio=0.21, 95% confidence interval [0.06; 0.68],
1108 $p=0.01$). **F.** IFN γ levels in whole blood samples from a cohort of COVID-19 negative or
1109 positive (convalescent) HCW (refer to Table S10) drawn pre- and post- vaccines, that were
1110 measured after a 22-hour stimulation with mitogens using a pool of overlapping RBD peptides
1111 (BioMérieux assay). Group comparisons were performed using two-sided paired Wilcoxon-
1112 Mann-Whitney test and asterisks indicate statistically significant differences ($*p<0.05$,
1113 $**p<0.01$, $***p<0.001$, $****p<0.0001$).

1114

1115

1116 **References:**

1117

1118 1. Chen, Z. & John Wherry, E. T cell responses in patients with COVID-19. *Nat Rev*
1119 *Immunol* **20**, 529–536 (2020).

1120 2. Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N*
1121 *Engl J Med* **384**, 403–416 (2021).

1122 3. Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N*
1123 *Engl J Med* **383**, 2603–2615 (2020).

1124 4. Walsh, E. E. *et al.* Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine
1125 Candidates. *N Engl J Med* **383**, 2439–2450 (2020).

1126 5. Bilich, T. *et al.* T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating
1127 long-term immune responses in COVID-19 convalescent individuals. *Sci. Transl. Med.*
1128 **13**, eabf7517 (2021).

1129 6. Garcia-Beltran, W. F. *et al.* Multiple SARS-CoV-2 variants escape neutralization by
1130 vaccine-induced humoral immunity.
1131 <https://medrxiv.org/lookup/doi/10.1101/2021.02.14.21251704> (2021)
1132 doi:[10.1101/2021.02.14.21251704](https://doi.org/10.1101/2021.02.14.21251704).

1133 7. Moore, J. P. Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of
1134 Viral Variants and Vaccine Efficacy. *JAMA* **325**, 1251 (2021).

1135 8. Channappanavar, R., Fett, C., Zhao, J., Meyerholz, D. K. & Perlman, S. Virus-Specific
1136 Memory CD8 T Cells Provide Substantial Protection from Lethal Severe Acute
1137 Respiratory Syndrome Coronavirus Infection. *Journal of Virology* **88**, 11034–11044
1138 (2014).

1139 9. Le Bert, N. *et al.* SARS-CoV-2-specific T cell immunity in cases of COVID-19 and
1140 SARS, and uninfected controls. *Nature* **584**, 457–462 (2020). 1.

1141 10. Ng, O.-W. *et al.* Memory T cell responses targeting the SARS coronavirus persist up to
1142 11 years post-infection. *Vaccine* **34**, 2008–2014 (2016).

1143 11. Zhao, J. *et al.* Airway Memory CD4 + T Cells Mediate Protective Immunity against
1144 Emerging Respiratory Coronaviruses. *Immunity* **44**, 1379–1391 (2016).

1145 12. Mosmann, T. R. & Coffman, R. L. TH1 and TH2 Cells: Different Patterns of
1146 Lymphokine Secretion Lead to Different Functional Properties. *Annu. Rev. Immunol.* **7**,
1147 145–173 (1989).

- 1148 13. Romagnani, S. Biology of human TH1 and TH2 cells. *J Clin Immunol* **15**, 121–129
1149 (1995).
- 1150 14. Romagnani, S. & Maggi, E. Th1 versus Th2 responses in AIDS. *Current Opinion in*
1151 *Immunology* **6**, 616–622 (1994).
- 1152 15. Ruterbusch, M., Pruner, K. B., Shehata, L. & Pepper, M. In Vivo CD4⁺ T Cell
1153 Differentiation and Function: Revisiting the Th1/Th2 Paradigm. *Annu. Rev. Immunol.*
1154 **38**, 705–725 (2020).
- 1155 16. Dan, J. M. *et al.* Immunological memory to SARS-CoV-2 assessed for up to 8 months
1156 after infection. *Science* **371**, eabf4063 (2021).
- 1157 17. Habel, J. R. *et al.* Suboptimal SARS-CoV-2-specific CD8⁺ T cell response
1158 associated with the prominent HLA-A*02:01 phenotype. *Proc Natl Acad Sci USA* **117**,
1159 24384–24391 (2020).
- 1160 18. Oxford Immunology Network Covid-19 Response T cell Consortium *et al.* Broad and
1161 strong memory CD4⁺ and CD8⁺ T cells induced by SARS-CoV-2 in UK convalescent
1162 individuals following COVID-19. *Nat Immunol* **21**, 1336–1345 (2020).
- 1163 19. Rodda, L. B. *et al.* Functional SARS-CoV-2-Specific Immune Memory Persists after
1164 Mild COVID-19. *Cell* **184**, 169-183.e17 (2021).
- 1165 20. Sekine, T. *et al.* Robust T Cell Immunity in Convalescent Individuals with
1166 Asymptomatic or Mild COVID-19. *Cell* **183**, 158-168.e14 (2020).
- 1167 21. Bacher, P. *et al.* Low-Avidity CD4⁺ T Cell Responses to SARS-CoV-2 in Unexposed
1168 Individuals and Humans with Severe COVID-19. *Immunity* **53**, 1258-1271.e5 (2020).
- 1169 22. Lee, J.-S. *et al.* Evidence of Severe Acute Respiratory Syndrome Coronavirus 2
1170 Reinfection After Recovery from Mild Coronavirus Disease 2019. *Clinical Infectious*
1171 *Diseases* ciaa1421 (2020) doi:[10.1093/cid/ciaa1421](https://doi.org/10.1093/cid/ciaa1421).
- 1172 23. Braun, J. *et al.* SARS-CoV-2-reactive T cells in healthy donors and patients with
1173 COVID-19. *Nature* **587**, 270–274 (2020).
- 1174 24. Grifoni, A. *et al.* Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans
1175 with COVID-19 Disease and Unexposed Individuals. *Cell* **181**, 1489-1501.e15 (2020).
- 1176 25. Dykema, A. G. *et al.* Functional characterization of CD4⁺ T cell receptors crossreactive
1177 for SARS-CoV-2 and endemic coronaviruses. *Journal of Clinical Investigation* **131**,
1178 e146922 (2021).
- 1179 26. Goubet, A.-G. *et al.* Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are
1180 hallmarks of COVID-19 in cancer patients with poor prognosis.
1181 <https://medrxiv.org/lookup/doi/10.1101/2021.04.26.21250357> (2021)
1182 doi:[10.1101/2021.04.26.21250357](https://doi.org/10.1101/2021.04.26.21250357).
- 1183 27. Andre, F. *et al.* Malignant effusions and immunogenic tumour-derived exosomes. *The*
1184 *Lancet* **360**, 295–305 (2002).
- 1185 28. Besse, B. *et al.* Dendritic cell-derived exosomes as maintenance immunotherapy after
1186 first line chemotherapy in NSCLC. *OncoImmunology* **5**, e1071008 (2016).
- 1187 29. Borg, C. *et al.* Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK
1188 cell-dependent antitumor effects. *J. Clin. Invest.* **114**, 379–388 (2004).
- 1189 30. Wemeau, M. *et al.* Calreticulin exposure on malignant blasts predicts a cellular
1190 anticancer immune response in patients with acute myeloid leukemia. *Cell Death Dis* **1**,
1191 e104–e104 (2010).
- 1192 31. Mateus, J. *et al.* Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed
1193 humans. *Science* **370**, 89–94 (2020).
- 1194 32. Nelde, A. *et al.* SARS-CoV-2-derived peptides define heterologous and COVID-19-
1195 induced T cell recognition. *Nat Immunol* **22**, 74–85 (2021).

- 1196 33. Le Bert, N. *et al.* Highly functional virus-specific cellular immune response in
1197 asymptomatic SARS-CoV-2 infection. *Journal of Experimental Medicine* **218**,
1198 e20202617 (2021).
- 1199 34. Zhao, Y. *et al.* Clonal expansion and activation of tissue-resident memory-like T_H 17
1200 cells expressing GM-CSF in the lungs of patients with severe COVID-19. *Sci. Immunol.*
1201 **6**, eabf6692 (2021).
- 1202 35. Fournier, P.-E. *et al.* Emergence and outcomes of the SARS-CoV-2 ‘Marseille-4’
1203 variant. *International Journal of Infectious Diseases* **106**, 228–236 (2021).
- 1204 36. Cha, E. *et al.* Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4
1205 Treatment in Cancer Patients. *Science Translational Medicine* **6**, 238ra70-238ra70
1206 (2014).
- 1207 37. Scheper, W. *et al.* Low and variable tumor reactivity of the intratumoral TCR repertoire
1208 in human cancers. *Nat Med* **25**, 89–94 (2019).
- 1209 38. Yager, E. J. *et al.* Age-associated decline in T cell repertoire diversity leads to holes in
1210 the repertoire and impaired immunity to influenza virus. *Journal of Experimental*
1211 *Medicine* **205**, 711–723 (2008).
- 1212 39. Shang, J. *et al.* Structural basis of receptor recognition by SARS-CoV-2. *Nature* **581**,
1213 221–224 (2020).
- 1214 40. Low, J. S. *et al.* Clonal analysis of immunodominance and cross-reactivity of the CD4
1215 T cell response to SARS-CoV-2. *Science* eabg8985 (2021)
- 1216 41. Gaebler, C. *et al.* Evolution of antibody immunity to SARS-CoV-2. *Nature* **591**, 639–
1217 644 (2021).
- 1218 42. Mouton, W. *et al.* A novel whole-blood stimulation assay to detect and quantify memory
1219 T-cells in COVID-19 patients.
1220 <http://medrxiv.org/lookup/doi/10.1101/2021.03.11.21253202> (2021)
1221 doi:[10.1101/2021.03.11.21253202](https://doi.org/10.1101/2021.03.11.21253202).
- 1222 43. Whitmire, J. K., Asano, M. S., Murali-Krishna, K., Suresh, M. & Ahmed, R. Long-Term
1223 CD4 Th1 and Th2 Memory following Acute Lymphocytic Choriomeningitis Virus
1224 Infection. *J Virol* **72**, 8281–8288 (1998).
- 1225 44. Hondowicz, B. D., Kim, K. S., Ruterbusch, M. J., Keitany, G. J. & Pepper, M. IL-2 is
1226 required for the generation of viral-specific CD4⁺ Th1 tissue-resident memory cells and
1227 B cells are essential for maintenance in the lung. *Eur. J. Immunol.* **48**, 80–86 (2018).
- 1228 45. Li, C. K. *et al.* T Cell Responses to Whole SARS Coronavirus in Humans. *J Immunol*
1229 **181**, 5490–5500 (2008).
- 1230 46. Page, C. *et al.* Induction of Alternatively Activated Macrophages Enhances
1231 Pathogenesis during Severe Acute Respiratory Syndrome Coronavirus Infection.
1232 *Journal of Virology* **86**, 13334–13349 (2012).
- 1233 47. Yale IMPACT Team *et al.* Longitudinal analyses reveal immunological misfiring in
1234 severe COVID-19. *Nature* **584**, 463–469 (2020).
- 1235 48. Kumamoto, Y. *et al.* CD301b⁺ Dermal Dendritic Cells Drive T Helper 2 Cell-Mediated
1236 Immunity. *Immunity* **39**, 733–743 (2013).
- 1237 49. Sokol, C. L., Camire, R. B., Jones, M. C. & Luster, A. D. The Chemokine Receptor
1238 CCR8 Promotes the Migration of Dendritic Cells into the Lymph Node Parenchyma to
1239 Initiate the Allergic Immune Response. *Immunity* **49**, 449-463.e6 (2018).
- 1240 50. Van Dyken, S. J. *et al.* A tissue checkpoint regulates type 2 immunity. *Nat Immunol* **17**,
1241 1381–1387 (2016).
- 1242 51. Sánchez-Cerrillo, I. *et al.* COVID-19 severity associates with pulmonary redistribution
1243 of CD1c⁺ DCs and inflammatory transitional and nonclassical monocytes. *Journal of*
1244 *Clinical Investigation* **130**, 6290–6300 (2020).

- 1245 52. Becattini, S. *et al.* Functional heterogeneity of human memory CD4⁺ T cell clones
1246 primed by pathogens or vaccines. *Science* **347**, 400–406 (2015).
- 1247 53. Honda, T. *et al.* Tuning of Antigen Sensitivity by T Cell Receptor-Dependent Negative
1248 Feedback Controls T Cell Effector Function in Inflamed Tissues. *Immunity* **40**, 235–
1249 247 (2014).
- 1250 54. Shinoda, K. *et al.* Thy1⁺ IL-7⁺ lymphatic endothelial cells in iBALT provide a survival
1251 niche for memory T-helper cells in allergic airway inflammation. *Proceedings of the*
1252 *National Academy of Sciences* **113**, E2842–E2851 (2016).
- 1253 55. Yeon, S. *et al.* IL-7 plays a critical role for the homeostasis of allergen-specific memory
1254 CD4 T cells in the lung and airways. *Scientific Reports* **7**, (2017).
- 1255 56. Meckiff, B. J. *et al.* Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive
1256 CD4⁺ T Cells in COVID-19. *Cell* **183**, 1340-1353.e16 (2020).
- 1257 57. Weiskopf, D. *et al.* Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-
1258 19 patients with acute respiratory distress syndrome. *Science Immunology* **5**, eabd2071
1259 (2020).
- 1260 58. Bacher, P. *et al.* Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-
1261 Reactivity against *Candida albicans*. *Cell* **176**, 1340-1355.e15 (2019).
- 1262 59. Greiling, T. M. *et al.* Commensal orthologs of the human autoantigen Ro60 as triggers
1263 of autoimmunity in lupus. *Science Translational Medicine* **10**, eaan2306 (2018).
- 1264 60. Koutsakos, M. *et al.* Human CD8⁺ T cell cross-reactivity across influenza A, B and C
1265 viruses. *Nature Immunology* **20**, 613–625 (2019).
- 1266 61. Sridhar, S. *et al.* Cellular immune correlates of protection against symptomatic
1267 pandemic influenza. *Nature Medicine* **19**, 1305–1312 (2013).
- 1268 62. Welsh, R. M., Che, J. W., Brehm, M. A. & Selin, L. K. Heterologous immunity between
1269 viruses: Heterologous immunity between viruses. *Immunological Reviews* **235**, 244–
1270 266 (2010).
- 1271 63. Woodland, D. L. & Blackman, M. A. Immunity and age: living in the past? *Trends in*
1272 *Immunology* **27**, 303–307 (2006).
- 1273 64. Tarke, A. *et al.* Comprehensive analysis of T cell immunodominance and
1274 immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. *Cell Reports*
1275 *Medicine* **2**, 100204 (2021).
- 1276 65. Tan, A. T. *et al.* Early induction of functional SARS-CoV-2-specific T cells associates
1277 with rapid viral clearance and mild disease in COVID-19 patients. *Cell Reports* **34**,
1278 108728 (2021).
- 1279 66. Hansen, T. H. & Bouvier, M. MHC class I antigen presentation: learning from viral
1280 evasion strategies. *Nature Reviews Immunology* **9**, 503–513 (2009).
- 1281 67. Hachim, A. *et al.* ORF8 and ORF3b antibodies are accurate serological markers of early
1282 and late SARS-CoV-2 infection. *Nature Immunology* **21**, 1293–1301 (2020).
- 1283 68. Young, B. E. *et al.* Effects of a major deletion in the SARS-CoV-2 genome on the
1284 severity of infection and the inflammatory response: an observational cohort study. *The*
1285 *Lancet* **396**, 603–611 (2020).
- 1286 69. Su, Y. C. F. *et al.* Discovery and Genomic Characterization of a 382-Nucleotide
1287 Deletion in ORF7b and ORF8 during the Early Evolution of SARS-CoV-2. *mBio* **11**,
1288 (2020).
- 1289 70. Greaney, A. J. *et al.* Complete Mapping of Mutations to the SARS-CoV-2 Spike
1290 Receptor-Binding Domain that Escape Antibody Recognition. *Cell Host & Microbe* **29**,
1291 44-57.e9 (2021).
- 1292 71. Koenig, P.-A. *et al.* Structure-guided multivalent nanobodies block SARS-CoV-2
1293 infection and suppress mutational escape. *Science* **371**, eabe6230 (2021).

- 1294 72. Agerer, B. *et al.* SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8⁺ T
1295 cell responses. *Science Immunology* **6**, eabg6461 (2021).
1296 73. Iwasaki, A. & Omer, S. B. Why and How Vaccines Work. *Cell* **183**, 290–295 (2020).
1297 74. Bolles, M. *et al.* A Double-Inactivated Severe Acute Respiratory Syndrome
1298 Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased
1299 Eosinophilic Proinflammatory Pulmonary Response upon Challenge. *Journal of*
1300 *Virology* **85**, 12201–12215 (2011).
1301 75. Tseng, C.-T. *et al.* Immunization with SARS Coronavirus Vaccines Leads to Pulmonary
1302 Immunopathology on Challenge with the SARS Virus. *PLoS ONE* **7**, e35421 (2012).
1303 76. Jiang, S. *et al.* Roadmap to developing a recombinant coronavirus S protein receptor-
1304 binding domain vaccine for severe acute respiratory syndrome. *Expert Review of*
1305 *Vaccines* **11**, 1405–1413 (2012).
1306 77. Martins, K. A., Bavari, S. & Salazar, A. M. Vaccine adjuvant uses of poly-IC and
1307 derivatives. *Expert Review of Vaccines* **14**, 447–459 (2015).
1308 78. Jo, W. K., Drosten, C. & Drexler, J. F. The evolutionary dynamics of endemic human
1309 coronaviruses. *Virus Evolution* **7**, (2021).
1310 79. Chaput, N. *et al.* Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR
1311⁺ NK cell levels correlate with disease outcome. *OncoImmunology* **2**, e23080 (2013).
1312 80. Fournier, P.-E. *et al.* Emergence and outcomes of the SARS-CoV-2 ‘Marseille-4’
1313 variant. *International Journal of Infectious Diseases* **106**, 228–236 (2021).
1314 81. Sahin, U. *et al.* BNT162b2 vaccine induces neutralizing antibodies and poly-specific T
1315 cells in humans. *Nature* (2021) doi:[10.1038/s41586-021-03653-6](https://doi.org/10.1038/s41586-021-03653-6).
1316 82. Saini, S. K. *et al.* SARS-CoV-2 genome-wide T cell epitope mapping reveals
1317 immunodominance and substantial CD8⁺ T cell activation in COVID-19 patients.
1318 *Science Immunology* **6**, eabf7550 (2021).
1319 83. Shomuradova, A. S. *et al.* SARS-CoV-2 Epitopes Are Recognized by a Public and
1320 Diverse Repertoire of Human T Cell Receptors. *Immunity* **53**, 1245-1257.e5 (2020).

1321

1322 **Supplementary materials**

1323

1324 **Figure S1. Cross-presentation *in vitro* assay at the acute and convalescent phase of** 1325 **COVID-19.**

1326 **A.** Prototypical example of the result of the assay detailed in Figure 1B and M&M for one
1327 COVID-19 negative cancer patient. Each box plot represents the absolute values of cytokine
1328 secretion of two replicate wells in the 12 plex flow cytometric assay, in the 48hr supernatants
1329 of PBL stimulated with DC pulsed with SARS-CoV-2 versus Vero E6 (negative control) and
1330 the other common cold coronaviruses and their respective control cell line (negative controls).
1331 Each dot represents each replicate well for each stimulatory condition for one patient. Positive
1332 control: PBL stimulated with anti-CD3 and anti-CD28 antibody coated beads. **B.** MHC class I
1333 and class II neutralization experiments. Neutralizing anti-HLA-ABC and HLA-DR, DP, DQ
1334 antibodies (W6/32 & Tu39) were used to block the specific PBL reactivities in the above assay.
1335 **C.** Idem as in Figure 1D showing the other 6 cytokine ratios. **D.** Spearman correlation between
1336 SARS-CoV-2-specific IL-2 release and non-activated TFH. Group comparisons were

1337 performed using two-sided Wilcoxon-Mann-Whitney test and the asterisks indicate statistically
1338 significant differences ($*p<0.05$, $**p<0.01$, $***p<0.001$, $****p<0.0001$).

1339

1340 **Figure S2. Detailed SARS-CoV-2 and CCC-specific cytokine release for convalescent**
1341 **COVID-19 patients compared with unexposed individuals.**

1342 **A.** Non supervised hierarchical clustering of SARS-CoV-2 and CCC- specific cytokine release
1343 in all patients. Heatmap of cytokine release for SARS-CoV-2 or CCC in the cross-presentation
1344 assay performed at the convalescent phase of COVID-19 (n=54) and in unexposed individuals
1345 (n=304), aligning all 12 cytokines and all subject categories. **B.** Polyfunctional T cell responses
1346 among subjects from various cohorts. Individuals who exhibited SARS-CoV-2-specific release
1347 of one or several cytokines are enumerated in each bar. Each bar indicates a category of patients
1348 or subjects as described in Figure 1A. **C.** Percentage and number of patients in each cohort (Pre-
1349 COVID19 era (yes (+)/no(-)), Cancer (yes (+)/no(-) and COVID-19 (yes (+)/no(-)) who had a
1350 SARS-CoV-2-specific cytokine release (for the 5 statistically significant cytokines at the
1351 convalescent phase) compared with VeroE6 (Control, n=304; Convalescent, n=54). Asterisks
1352 indicate statistically significant differences of SARS-CoV-2-specific cytokine release
1353 proportions between two groups determined using Fisher exact test ($*p<0.05$).

1354

1355 **Figure S3. TH1/TC1 differentiation patterns in susceptible versus resistant individuals.**

1356 **A-B.** Unsupervised hierarchical clustering of SARS-CoV-2-specific cytokine release. Heatmap
1357 of cytokine release in the cross-presentation assay performed during the first surge of the
1358 pandemic in unexposed individuals (n=60), aligning cytokines in the two subject categories,
1359 susceptible (persons who got infected during the second or the third surge of the pandemic)
1360 versus resistant (contact) individuals. Group comparisons were performed using a two-sided
1361 Wilcoxon-Mann-Whitney test. **C-D.** Spearman correlation matrices between cytokine levels in
1362 susceptible (n=19, C) versus resistant (n=41, D) individuals, respectively. The asterisks indicate
1363 statistically significant differences ($p<0.05$). **E.** Dynamic study of the stability of the TH1/TH2
1364 profile in individuals that were followed up at two time points. Ratio of cytokine release at the
1365 acute and convalescent phase (left panel) and corresponding IL-2/IL-5 ratio (right panel) in 5
1366 cancer patients. Two-sided Wilcoxon-Mann-Whitney test did not reveal significant difference
1367 between both time points.

1368

1369 **Figure S4. Waterfall plots indicating the IL-2/IL-5 ratio in all patient or individual**
1370 **groups.**

1371 Waterfall plot between IL-2 and IL-5 ratio of cytokine release in the Figure 1B IVS assay in all
1372 patients during the first surge of the pandemic depicting cancer (green) versus cancer free (blue)
1373 COVID-19+ convalescent patients (A), resistant (orange) versus susceptible (red) (B), locked
1374 down (or unknown) subjects (dark green, n=301) and healthy individuals in contact with their
1375 COVID-19+ family members (light green) (D). Each bar represents one patient. Proportion of
1376 patients exhibiting an IL-2/IL-5 ratio superior or inferior to 1 is indicated in each panel. Clinical
1377 conditions are annotated as 0, +, ++, +++ for asymptomatic, mild, moderate, and severe
1378 COVID-19 severity, respectively. Refer to Figure 2F where percentages are compared
1379 inbetween groups.

1380

1381 **Figure S5. Cross-presentation assays using viral variants.**

1382 **A.** Cytokine ratio in the cross-presentation assay detailed in Figure 1B, using the original strain
1383 IHUMI846 (early 2020 episode) (CoV-2 in (A)), versus the Danish mink (B.1.160, 20A.EU2,
1384 GH) and North African (B.1.367, 20C, GH) strains in 25 control individuals. Statistical
1385 comparisons were performed using paired two-sided Wilcoxon-Mann-Whitney test and the
1386 asterisks indicate statistically significant differences ($*p<0.05$, $**p<0.01$, $***p<0.001$,
1387 $****p<0.0001$). **B.** Percentage and number of patients in Fig2J right panel who had a SARS-
1388 CoV-2-specific IL-2 release. Of note, only 4 re-infected patients could be tested because DC
1389 could not be differentiated into monocytes in the others to allow the cross-presentation assay.
1390 **C.** Similar experimental setting as in Figure 1B but loading lysates from various SARS-CoV-2
1391 strains (original one IHUMI846 (early 2020 episode), as well as IHUMI3076 (UK variant,
1392 B.1.1.7), IHUMI3147 (South African variant, B.1.351) and IHUMI3191 (Brazilian variant, P.1)
1393 strains isolated from human nasopharyngeal swab as previously described [35]. Heatmap of the
1394 intensity of the ratios between means of cytokine levels (of experimental replicates) obtained
1395 from PBL in coculture with DC+ IHUMI846 *versus* DC+ each variant.

1396

1397 **Figure S6. Percentages of patients reacting to each peptide and of peptides recognized by**
1398 **each individual in various groups or cohorts.**

1399 Bar plot of the percentage of patients recognizing a given peptide. Blue and green lines
1400 represent the frequency of peptide recognition in control versus convalescent individuals
1401 respectively. Inset. Bar plot of the percentage of positive peptides in the IFN γ ELISA per
1402 patient. The color code indicates patient category (blue for control, green for convalescent
1403 COVID-19, purple for re-infected patients).

1404

1405 **Figure S7. Peptide recognition mapping in various categories of individuals.**

1406 Mean frequencies of IFN γ ELISA positivity in the peptide IVS assay (described in Figure 3A)
1407 for each indicated protein of the ORFeome in each subject category, for each individual peptide
1408 (each line corresponding to one peptide) in 159 subjects.

1409

1410 **Figure S8. Correlation of secretory profiles for each peptide in the IVS assay.**

1411 Scatter plot of peptides according to the percentage of patients reacting in IFN γ or IL-9
1412 secretion (n=43, A) IL-17 (n=23, B) or IL-5 (n=64, C). The distance to the diagonal is indicated
1413 by a gradient of color.

1414

1415 **Figure S9. Logistic regression analyses identifying cohort -specific fingerprints of T cell
1416 repertoires.**

1417 **A.** Statistically significant peptide signatures in the peptide-based IVS assay (Figure 3A) using
1418 a multivariable logistic regression analysis adjusted for period (pre-COVID-19 era or
1419 contemporary patients), COVID-19 history and cancer (refer to Table S2). The left column
1420 shows variables, and the x axis indicates the significant peptides (pval<0.05). The magnitude
1421 of the log (Odd Ratio) is indicated in the red/blue color code while that of the p-value is
1422 represented by the circle size. **B-C.** Percentages of patients recognizing at least one peptide
1423 from the pre-COVID-19 (B) or convalescent (C) signature identified in the logistic regression
1424 analyses of panel A in the IFN γ ELISA in the peptide IVS assay. Fisher's exact test to compare
1425 the number of patients positive for each signature between groups (*p<0.05, **p<0.01).

1426

1427 **Supplemental Tables**

1428

1429 **Table S1. Consort diagram.** Flow diagram showing the enrollment of subjects, their allocation
1430 to different cohorts and how they are analyzed in the trial.

1431 **Table S2. Characteristics of cancer patients and healthy volunteers.**

1432 **Table S3. Characteristics of family members during the 2020 lock down.**

1433 **Table S4. Characteristics of contact (resistant) and infected (susceptible) cancer patients
1434 and corresponding swimmer plot for the outcome of the susceptible cases.**

1435 Individual swimmer plots for each susceptible individual (*i.e.* who got infected during the
1436 second or the third surge of the pandemic) depicting patients still alive (blue), patients dead
1437 from cancer, and patients dead from COVID-19 (red) after infection indicated with an arrow.

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

1438 **Table S5. Characteristics of multi-exposed cases and re-infected cancer -free individuals.**

1439 **Table S6. SARS-CoV-1 and CoV-2 orfeome peptide list: sequences and positions.**

1440 **Table S7. Peptide-specific T cell polarization determined by IL-5 or IFN γ quantification.**

1441 **Table S8. HLA binding affinities of the S1-RBD peptides using the NetMHCpan**

1442 **algorithm**

1443 **Table S9. Mutational hotspots in the peptide residues.**

1444 **Table S10. Characteristics of vaccinated healthcare workers.**

1445

1446

1447




Figure 1




Figure 2






Figure 3




Figure 4







Figure S1






Figure S2








Figure S3









Figure S4

A.



B.



C.




Figure S5




Figure S6






Figure S7

A.



B.



C.






Figure S8

A



B



C




Figure S9

Table S1. Consort diagram




Table S2. Characteristics of cancer patients and healthy individuals.

		Controls (n=320)		Acute COVID-19 (n=40)		P.value*	Convalescent (n=69)		P.value #
		n	%	n	%		n	%	
Years	2000 - Nov. 2002	7	2	-	-	< 0.01	-	-	< 0.01
	Nov. 2002 - 2018	61	19	-	-		-	-	
	Unknown	2	1	-	-		-	-	
	2020 - 2021	250	78	40	100		69	100	
Age (years)	Median [Range]	61 [18-89]		63 [20-90]		0.13	56 [21-85]		0.02
Gender	Male	124	45	22	55	0.31	28	41	0.05
	Female	150	55	18	45		41	59	
	Unknown	46	-	-	-		-	-	
Malignancy	Yes	257	80	40	100	< 0.01	40	58	< 0.01
	No	63	20	0	0		29	42	

Refers to available samples described in table S1

* : statistical analyses between controls and acute COVID-19;


: statistical analyses between controls and convalescent

Table S3. Characteristics of family members during the 2020 lockdown.

		Total		Contact (n=22)		Convalescent (n=29)		P.value
Age (years)	Median [Range]	46 [17-75]		39 [17-75]		49 [20-62]		0.69
Gender	Male	n	%	n	%	n	%	0.40
	Female	26	51	13	59	13	45	
Number of contacts per case within the family								< 0.01
1-3				5	23	1	3	
4-6				14	64	15	52	
7-9				1	5	8	28	
10-12				2	9	0	0	
> 12				0	0	5	17	
Number of SARS-CoV-2 positive individuals in the family								< 0.01
0				4	18	0	0	
1-3				18	82	18	62	
4-6				0	0	5	17	
7-15				0	0	6	21	
Household size								< 0.01
0				2	9	0	0	
1-2				0	0	5	17	
3-5				18	82	16	55	
6-8				2	9	8	28	
Household living space (m²)								0.16
< 70				7	32	6	21	
70-100				3	14	11	38	
> 100				12	55	12	41	
Number of rooms in the household								0.22
2-3				10	45	7	24	
4-5				6	27	14	48	
6-8				6	27	8	28	
Number of individuals using personal protective equipment				13	59	18	62	1
Number of individuals respecting barriers gestures				16	73	22	76	1

Table S4. Clinical characteristics of all contact cases (susceptible and resistant).

	Median [Range]	Resistant (n=48)		Susceptible (n=22)		P.value
		n	%	n	%	
Age (years)		57		54		0.84
		[21-77]		[23-82]		
Gender	Male	16	33	11	50	0.20
	Female	32	67	11	50	
Malignancy	Yes	48	100	22	100	1.00
	No	0	0	0	0	



- Time from study inclusion to infection
- Infection
- Death
- End of follow up
- Still alive
- Death of cancer
- Death of COVID-19

Table S5. Characteristics of multi-exposed and re-infected cancer-free individuals.

		Re-infected (n=17)		Multi-exposed cases (n=12)		P.value
Age (years)	Median	37		48		0.08
	[Range]	[16-78]		[28-69]		
Gender		n	%	n	%	0.72
	Male	7	41	6	50	
	Female	10	59	6	50	
Comorbidities	Yes	5	31	-	-	-
	No	11	69	-	-	
	Unknown	1	-	-	-	
Type of comorbidities	Asthma	3	60	-	-	-
	Obesity	2	40	-	-	
	Type 2 diabetes	2	40	-	-	
	Cancer		20	-	-	
	HIV*	1	20	-	-	
	HBP**	2	40	-	-	
Time to reinfection (mo.)	< 03	2	17	-	-	-
	03 - 06	7	58	-	-	
	> 06	3	25	-	-	
	Unknown	5	-	-	-	
Second surge variants	B.1.177	1	-	-	-	-
	B.1.160	6	-	-	-	
	B.1.351	1	-	-	-	
	B.1.1.7	2	-	-	-	
	Unknown	7	-	-	-	

Refers to eligible patients described in table S1

*Human Immunodeficiency Virus

**High Blood Pressure

Table S7. Peptide-specific T cell polarisation determined by IL-5 or IFN γ quantification.

SARS-CoV-2 protein		n	IL-5 ⁻ /IFN γ ⁻	IL-5 ⁺ /IFN γ ⁻	IL-5 ⁻ /IFN γ ⁺	IL-5 ⁺ /IFN γ ⁺	P.value
Membrane	Resistant	35	20	3	1	1	0.76
	Susceptible		10	0	0	0	
Nucleocapsid	Resistant	42	17	3	7	3	0.58
	Susceptible		9	0	3	0	
S1	Resistant	36	15	0	9	4	0.34
	Susceptible		7	0	1	0	
S1-RBD	Resistant	36	15	3	10	0	0.06
	Susceptible		8	0	0	0	
S2	Resistant	23	8	0	7	1	0.75
	Susceptible		5	0	2	0	
ORF8	Resistant	22	11	0	5	0	1.00
	Susceptible		4	0	2	0	
ORF10	Resistant	23	15	0	1	0	0.53
	Susceptible		6	0	1	0	
ORF3a	Resistant	22	14	0	1	0	1.00
	Susceptible		7	0	0	0	

The numbers correspond to the enumeration of patients who were positive for at least one of the epitopes of each protein listed in Table S6.

Table S10. Characteristics of vaccinated healthcare workers.

		Controls (n=70)		Convalescent (n=14)		P.value
Age (years)	Median	49		48		0.71
	[Range]	[21-76]		[28-69]		
		n	%	n	%	
Gender	Male	18	26	2	14	0.50
	Female	52	74	12	86	

Table S8a. HLA phenotyping and genotyping of susceptible and resistant individuals (class I).

Peptide sequence	Mutated and WT peptide name	HLA-A alleles																			
		Allele freq.(%)																			
		HLA-A*02:01	HLA-A*03:01	HLA-A*03:01	HLA-A*24:02	HLA-A*11:01	HLA-A*26:01	HLA-A*23:01	HLA-A*23:01	HLA-A*23:01	HLA-A*23:01	HLA-A*23:01	HLA-A*23:01	HLA-A*23:01	HLA-A*23:01	HLA-A*23:01	HLA-A*23:01	HLA-A*23:01	HLA-A*23:01	HLA-A*23:01	HLA-A*23:01
RFASVYVWNRKRISN	Spike24wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
CVADYVSLYNASFS	Spike25wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
CVADYVSLYNASFS	Spike25_V367F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
TFKCYVGSPTKLNLDL	Spike26wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
CFNTVYADSFVIRGD	Spike27wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
EVROIAPGQTGIAD	Spike28wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
EVROIAPGQTGIAD	Spike28_K417N	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
EVROIAPGQTGIAD	Spike28_K417P	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
YNYKLPDFTGCVIA	Spike29wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
WNSNLDKSVGGNNY	Spike30wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
WNSNLDKSVGGNNY	Spike30_N439K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
WNSNLDKSVGGNNY	Spike30_N440K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
YLYRFRKSNLKPFE	Spike31wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
YLYRFRKSNLKPFE	Spike31_L452R	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
RDISTEIVGVSTPC	Spike32_A475V	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
RDISTEIVGVSTPC	Spike32wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
RDISTEIVGVSTPC	Spike32_S477N	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
RDISTEIVGVSTPC	Spike32_T478K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
NGVEGFNCYFPLQSY	Spike33wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
NGVKGFCNYFPLQSY	Spike33_E484K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
NGVKGFCNYFPLQSY	Spike33_E484Q	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
NGVEGFNCYFPLQSY	Spike33_Q493R	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
NGVEGFNCYFPLQSY	Spike33_V483A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
GFQPTNGVGYQPYRV	Spike34wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
GFQPTNGVGYQPYRV	Spike34_N501Y	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
VVLSFELLHAPATVC	Spike35wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

LEGEND:
 1 = no binding
 = weak binding(contains atleastone8-11mer weak binder)
 2 = strong binding(contains atleastone8-11mer strongbinder)

Peptide sequence	Mutated and WT peptide name	HLA-B alleles																			
		Allele freq.(%)																			
		HLA-B*07:02	HLA-B*08:01	HLA-B*08:01	HLA-B*08:01	HLA-B*08:01	HLA-B*08:01	HLA-B*08:01	HLA-B*08:01	HLA-B*08:01	HLA-B*08:01	HLA-B*08:01	HLA-B*08:01	HLA-B*08:01	HLA-B*08:01	HLA-B*08:01	HLA-B*08:01	HLA-B*08:01	HLA-B*08:01	HLA-B*08:01	HLA-B*08:01
RFASVYVWNRKRISN	Spike24wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
CVADYVSLYNASFS	Spike25wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
CVADYVSLYNASFS	Spike25_V367F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
TFKCYVGSPTKLNLDL	Spike26wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
CFNTVYADSFVIRGD	Spike27wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
EVROIAPGQTGIAD	Spike28wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
EVROIAPGQTGIAD	Spike28_K417N	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
EVROIAPGQTGIAD	Spike28_K417P	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
YNYKLPDFTGCVIA	Spike29wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
WNSNLDKSVGGNNY	Spike30wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
WNSNLDKSVGGNNY	Spike30_N439K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
WNSNLDKSVGGNNY	Spike30_N440K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
YLYRFRKSNLKPFE	Spike31wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
YLYRFRKSNLKPFE	Spike31_L452R	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
RDISTEIVGVSTPC	Spike32_A475V	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
RDISTEIVGVSTPC	Spike32wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
RDISTEIVGVSTPC	Spike32_S477N	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
RDISTEIVGVSTPC	Spike32_T478K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
NGVEGFNCYFPLQSY	Spike33wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
NGVKGFCNYFPLQSY	Spike33_E484K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
NGVKGFCNYFPLQSY	Spike33_E484Q	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
NGVEGFNCYFPLQSY	Spike33_Q493R	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
NGVEGFNCYFPLQSY	Spike33_V483A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
GFQPTNGVGYQPYRV	Spike34wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
GFQPTNGVGYQPYRV	Spike34_N501Y	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
VVLSFELLHAPATVC	Spike35wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Peptide sequence	Mutated and WT peptide name	HLA-C alleles																			
		Allele freq.(%)																			
		HLA-C*07:01	HLA-C*07:02	HLA-C*07:02	HLA-C*07:02	HLA-C*07:02	HLA-C*07:02	HLA-C*07:02	HLA-C*07:02	HLA-C*07:02	HLA-C*07:02	HLA-C*07:02	HLA-C*07:02	HLA-C*07:02	HLA-C*07:02	HLA-C*07:02	HLA-C*07:02	HLA-C*07:02	HLA-C*07:02	HLA-C*07:02	HLA-C*07:02
RFASVYVWNRKRISN	Spike24wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
CVADYVSLYNASFS	Spike25wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
CVADYVSLYNASFS	Spike25_V367F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
TFKCYVGSPTKLNLDL	Spike26wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
CFNTVYADSFVIRGD	Spike27wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
EVROIAPGQTGIAD	Spike28wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
EVROIAPGQTGIAD	Spike28_K417N	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
EVROIAPGQTGIAD	Spike28_K417P	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
YNYKLPDFTGCVIA	Spike29wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
WNSNLDKSVGGNNY	Spike30wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
WNSNLDKSVGGNNY	Spike30_N439K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
WNSNLDKSVGGNNY	Spike30_N440K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
YLYRFRKSNLKPFE	Spike31wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
YLYRFRKSNLKPFE	Spike31_L452R	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
RDISTEIVGVSTPC	Spike32_A475V	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
RDISTEIVGVSTPC	Spike32wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
RDISTEIVGVSTPC	Spike32_S477N	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
RDISTEIVGVSTPC	Spike32_T478K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
NGVEGFNCYFPLQSY	Spike33wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
NGVKGFCNYFPLQSY	Spike33_E484K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
NGVKGFCNYFPLQSY	Spike33_E484Q	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
NGVEGFNCYFPLQSY	Spike33_Q493R	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
NGVEGFNCYFPLQSY	Spike33_V483A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
GFQPTNGVGYQPYRV	Spike34wt																				

